<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005478.pub2" GROUP_ID="STROKE" ID="211901091215502276" MERGED_FROM="" MODIFIED="2008-09-03 20:56:16 +0200" MODIFIED_BY="Hazel Fraser" REVIEW_NO="0001" REVMAN_SUB_VERSION="5.0.15" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.0">
<COVER_SHEET MODIFIED="2008-09-03 20:56:16 +0200" MODIFIED_BY="Hazel Fraser">
<TITLE>Naftidrofuryl for acute stroke</TITLE>
<CONTACT MODIFIED="2008-09-03 20:56:16 +0200" MODIFIED_BY="Hazel Fraser"><PERSON ID="16501" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Jo</FIRST_NAME><LAST_NAME>Leonardi-Bee</LAST_NAME><SUFFIX>MSc PhD</SUFFIX><POSITION>Lecturer in Medical Statistics</POSITION><EMAIL_1>jo.leonardi-bee@nottingham.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Division of Epidemiology and Public Health</DEPARTMENT><ORGANISATION>The University of Nottingham</ORGANISATION><ADDRESS_1>Clinical Sciences Building</ADDRESS_1><ADDRESS_2>Nottingham City Hospital NHS Trust Campus, Hucknall Road</ADDRESS_2><CITY>Nottingham</CITY><ZIP>NG5 1PB</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 115 823 1933</PHONE_1><FAX_1>+44 115 823 1946</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-09-03 20:56:16 +0200" MODIFIED_BY="Hazel Fraser"><PERSON ID="16501" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Jo</FIRST_NAME><LAST_NAME>Leonardi-Bee</LAST_NAME><SUFFIX>MSc PhD</SUFFIX><POSITION>Lecturer in Medical Statistics</POSITION><EMAIL_1>jo.leonardi-bee@nottingham.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Division of Epidemiology and Public Health</DEPARTMENT><ORGANISATION>The University of Nottingham</ORGANISATION><ADDRESS_1>Clinical Sciences Building</ADDRESS_1><ADDRESS_2>Nottingham City Hospital NHS Trust Campus, Hucknall Road</ADDRESS_2><CITY>Nottingham</CITY><ZIP>NG5 1PB</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 115 823 1933</PHONE_1><FAX_1>+44 115 823 1946</FAX_1></ADDRESS></PERSON><PERSON ID="8172" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Timothy</FIRST_NAME><LAST_NAME>Steiner</LAST_NAME><POSITION>Reader in Clinical Physiology</POSITION><EMAIL_1>t.steiner@imperial.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Division of Neuroscience</DEPARTMENT><ORGANISATION>Imperial College London</ORGANISATION><ADDRESS_1>Charing Cross Campus</ADDRESS_1><ADDRESS_2>St. Dunstan's Road</ADDRESS_2><CITY>London</CITY><ZIP>W6 8RP</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 20 8846 1191</PHONE_1><FAX_1>+44 20 8846 1183</FAX_1></ADDRESS></PERSON><PERSON ID="16321" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Fiona</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Bath-Hextall</LAST_NAME><POSITION>Associate Professor, </POSITION><EMAIL_1>fiona.bath-hextall@nottingham.ac.uk</EMAIL_1><MOBILE_PHONE>07816925547</MOBILE_PHONE><ADDRESS><DEPARTMENT>School of Nursing, Faculty of Medicine and Health Science</DEPARTMENT><ORGANISATION>The University of Nottingham</ORGANISATION><ADDRESS_1>Room D83, Medical school</ADDRESS_1><ADDRESS_2>Queens medical centre</ADDRESS_2><CITY>Nottingham</CITY><ZIP>NG7 2UH</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 115 8230884</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-09-03 19:34:42 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="21" MONTH="12" YEAR="2006"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="11" YEAR="2006"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="30" MONTH="1" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2007"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="3" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-09-03 19:34:55 +0100" MODIFIED_BY="[Empty name]"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-09-03 19:45:44 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-09-03 19:36:28 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-09-03 19:35:43 +0100" MODIFIED_BY="[Empty name]">Naftidrofuryl for acute stroke</TITLE>
<SUMMARY_BODY MODIFIED="2008-09-03 19:36:28 +0100" MODIFIED_BY="[Empty name]">
<P>Stroke is the third most common cause of death and the commonest cause of disability in the western world. Stroke greatly adds to the burden on patients, carers, medical practitioners and health resources. The development of drugs to limit brain damage caused by stroke continues but no routine effective treatment has yet been identified. In previous years, naftidrofuryl has been considered as a potential treatment for acute stroke, but has been withdrawn from the market in the UK. This systematic review of six trials, involving 1274 participants, found there was not enough data to draw conclusions about the effectiveness of naftidrofuryl relating to survival or disability in the treatment of acute stroke.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Stroke is the third most common cause of death and the most common cause of disability in the western world. The development of drugs to limit the effects of brain damage caused by stroke continues but no routine effective treatment has yet been identified. Naftidrofuryl has been reported to be beneficial in the treatment of acute stroke in some studies, but it is unclear whether all of the evidence supports these findings.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the effects of naftidrofuryl in the acute phase of stroke.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Cochrane Stroke Group Trials Register (last searched November 2006); the Cochrane Central Register of Controlled Trials (CENTRAL), the Cochrane Database of Systematic Reviews, and the Database of Abstracts of Reviews of Effects (<I>The Cochrane Library</I> Issue 2, 2006); MEDLINE (1966 to July 2006); EMBASE (1980 to July 2006); Science Citation Index (1981 to July 2006); National Research Register (July 2006); LILACS Database (1982 to July 2006); metaRegister of Controlled Trials (mRCT) (July 2006); SUMsearch (July 2006). To identify further published, unpublished and ongoing studies we searched reference lists, handsearched conference proceedings and contacted pharmaceutical companies and authors of relevant articles.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>We included patients with acute ischaemic or haemorrhagic stroke clinically diagnosed by a medical practitioner with or without a computerised tomography (CT) scan.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two authors independently selected trials for inclusion, assessed trial quality, and extracted data using data extraction forms or, if available, re-analysed individual patient data. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Six trials involving 1274 participants were included. We found no significant benefits of naftidrofuryl compared with placebo in reducing the risks of mortality (pooled odds ratio (OR) 1.03, 95% confidence interval (CI) 0.78 to 1.36, six studies) or combined death or dependency/disability (pooled OR 0.94, 95% CI 0.70 to 1.16, three studies). Pooled results showed naftidrofuryl had no significant effect on systolic, diastolic or mean arterial blood pressure. No trials reported the effects of naftidrofuryl on the risk of early death or deterioration, quality of life, stroke recurrence, or discharge site. However, we found a trend towards an increase in risk of minor adverse events in patients taking naftidrofuryl (OR 1.99, 95% CI 0.96 to 4.11, P = 0.06).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>There is not enough evidence to support the use of naftidrofuryl in the treatment of acute ischaemic or haemorrhagic stroke. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-09-03 19:43:57 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2008-09-03 19:36:41 +0100" MODIFIED_BY="[Empty name]">
<P>Stroke is the third most common cause of death and the most common cause of disability in the western world. Stroke greatly adds to the burden on patients, carers, medical practitioners and health resources. Enormous efforts have focused on the development of drugs to limit brain damage caused by stroke; these efforts continue but no routine effective treatment has yet been identified.</P>
<P>Ischaemia occurs where the blood supply falls below the requirement of local metabolic demand. This is the normal cause of cerebral infarction. The severity of neuronal tissue damage caused by ischaemia depends on the degree and duration of reduced blood flow. One of the first biological responses to a decrease in local blood flow is the rapid development of collateral circulations. However, these collateral circulations may be slow in developing or may be incomplete in patients with arterial disease. The boundary between the normally perfused area and the ischaemic core is not clear cut but the area between these two regions is called the ischaemic penumbra where moderate blood flow exists. Reperfusion of the penumbra within a given time allows neurons to recover; however, as time goes by damage to this area becomes irreversible. The outcome in the ischaemic area depends on how many cells die when their metabolic needs have not been met, which reduces the overall metabolic demand. Various attempts have been made in the past to modify this situation. One approach could be to improve the efficiency of substrate use. One candidate agent, naftidrofuryl, has been shown to promote glucose consumption, increase the supply of adenosine triphosphate (ATP), and reduce levels of lactate in normal animal brain (<LINK REF="REF-Meynaud-1973" TYPE="REFERENCE">Meynaud 1973</LINK>) and in an animal model of total cerebral ischaemia (<LINK REF="REF-Meynaud-1975" TYPE="REFERENCE">Meynaud 1975</LINK>). If this occurs in human ischaemic brains then naftidrofuryl could offer protection against the harmful metabolic effects of cerebral ischaemia.</P>
<P>Blood pressure management in the acute phase of stroke remains unclear. Some researchers hypothesise that hypertension should be reduced, since it is associated with a poor outcome (<LINK REF="REF-Leonardi_x002d_Bee-2002" TYPE="REFERENCE">Leonardi-Bee 2002</LINK>); however others have hypothesised that it should be increased to improve perfusion to the penumbral region (<LINK REF="REF-Sandercock-1992" TYPE="REFERENCE">Sandercock 1992</LINK>). Naftidrofuryl is a vasoactive drug, and hence may improve outcome in the acute phase of stroke by altering blood pressure. A systematic review and meta-analysis of published data found naftidrofuryl had little effect on blood pressure (<LINK REF="REF-BASC-2000" TYPE="REFERENCE">BASC 2000</LINK>), however, the authors concluded that individual patient data would be needed for methodological reasons to allow for a more complete analysis to assess the relationship between blood pressure and outcome.</P>
<P>Naftidrofuryl is the acid oxalate of N-diethylaminoethyl-beta-(naphthyl-1)-beta-tetra-hydrofuryl-isobutyrate. It has been shown in the past to be non-toxic in animals and man (<LINK REF="STD-Robinson-1972" TYPE="STUDY">Robinson 1972</LINK>). Naftidrofuryl is a 5-HT2 serotonergic antagonist that indirectly prevents platelet aggregation and enhances metabolism without increasing oxygen consumption in damaged brain tissue in vitro, in animal experiments and in humans (<LINK REF="REF-Davies-1988" TYPE="REFERENCE">Davies 1988</LINK>; <LINK REF="REF-Leponcin-1982" TYPE="REFERENCE">Leponcin 1982</LINK>; <LINK REF="REF-Maloteaux-1986" TYPE="REFERENCE">Maloteaux 1986</LINK>; <LINK REF="REF-Yesavage-1982" TYPE="REFERENCE">Yesavage 1982</LINK>). Naftidrofuryl selectively inhibits the 5-HT2 receptor expressed on human endothelial cells. Endothelin-1, an endogenous vasodilator, has been shown to activate human platelets (<LINK REF="REF-Jagroop-2000" TYPE="REFERENCE">Jagroop 2000</LINK>). Therefore, the indirect antiplatelet effect of naftidrofuryl may contribute to an improvement in outcome following stroke by antagonising the action of endothelin-1 (<LINK REF="REF-Jagroop-2000" TYPE="REFERENCE">Jagroop 2000</LINK>). Analogues of naftidrofuryl were also considered in this review, which are defined as praxilene, dusodril, LS121, artocoron, EU1806, gevatran, iridus, sodipryl, di-actane, and Vascuprax.</P>
<SUBSECTION>
<HEADING LEVEL="2">Rationale for undertaking this review</HEADING>
<P>There is some evidence that naftidrofuryl may be safe and effective in acute stroke but the evidence has not been reviewed systematically and remains inconclusive. Consequently the use of naftidrofuryl in acute stroke varies widely; it is used in some developing countries but has been removed from the market for use in acute stroke in the UK. This prompted us to review all of the available evidence to assess whether naftidrofuryl in the acute phase of stroke (defined as within seven days post ictus) can impact on the risk of early death and late death or disability.</P>
</SUBSECTION>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the effects of naftidrofuryl in patients in the acute phase of stroke.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-09-03 19:41:24 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-09-03 19:36:59 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>All published and unpublished randomised controlled trials that evaluate the efficacy of naftidrofuryl or its analogues (defined as praxilene, dusodril, LS121, artocoron, EU1806, gevatran, iridus, sodipryl, di-actane, and Vascuprax) in acute stroke patients (within seven days post ictus) were considered in this review. Studies of patients with subarachnoid haemorrhage were excluded. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Any individual with acute ischaemic or haemorrhagic stroke (defined as within seven days post ictus) that has been clinically diagnosed by a medical practitioner with or without a computerised tomography (CT) scan, was considered eligible for inclusion. </P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>All doses of naftidrofuryl or its analogues (defined as praxilene, dusodril, LS121, artocoron, EU1806, gevatran, iridus, sodipryl, di-actane, and Vascuprax) for acute stroke were considered and the following comparisons were made:<BR/>(1) any oral or intravenous treatment versus no treatment or placebo;<BR/>(2) any oral or intravenous treatment in combination with a second agent versus second agent alone;<BR/>(3) any oral or intravenous treatment versus any other treatment (these studies will be analysed separately from the other studies). </P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-09-03 19:36:59 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome measures</HEADING>
<P>(1) Late death (at end of scheduled follow up)<BR/>(2) Late death or disability or dependency (at end of scheduled follow up)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcome measures</HEADING>
<P>(1) Early death (within one month of randomisation)<BR/>(2) Early death or deterioration (within one month of randomisation)<BR/>(3) Quality of life (at end of scheduled follow up)<BR/>(4) Length of stay<BR/>(5) Stroke recurrence (at any time during scheduled follow up)<BR/>(6) Discharge site (death, institution, home)<BR/>(7) Blood pressure<BR/>(8) Serious adverse events (requiring withdrawal of the treatment)<BR/>(9) Minor adverse events (not requiring withdrawal of the treatment)</P>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-09-03 19:40:52 +0100" MODIFIED_BY="[Empty name]">
<P>See: 'Specialized register' section in <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/STROKE/frame.html">Cochrane Stroke Group</A>
</P>
<SUBSECTION>
<HEADING LEVEL="3">Electronic databases</HEADING>
<P>We searched the following bibliographic databases and ongoing trials and research registers (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>):<BR/>(1) the Cochrane Stroke Group Trials Register (last searched by the Review Group Co-ordinator in November 2006);<BR/>(2) the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> Issue 2, 2006);<BR/>(3) the Cochrane Database of Systematic Reviews (<I>The Cochrane Library</I> Issue 2, 2006);<BR/>(4) the Database of Abstracts of Reviews of Effects (<I>The Cochrane Library</I> Issue 2, 2006);<BR/>(5) MEDLINE (1966 to July 2006);<BR/>(6) EMBASE (1980 to July 2006);<BR/>(7) Science Citation Index (1981 to July 2006);<BR/>(8) National Research Register (http://www.nrr.nhs.uk/search.htm) (July 2006);<BR/>(9) LILACS (Latin American and Caribbean Health Science Literature) (1982 to July 2006);<BR/>(10) metaRegister of Controlled Trials (mRCT) (http://www.controlled-trials.com/) (July 2006); and<BR/>(11) SUMsearch, which searches the Internet for medical evidence (http://sumsearch.uthscsa.edu/) (July 2006).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">References from published studies</HEADING>
<P>We scanned the bibliographies of the identified studies and previous reviews of acute stroke management for possible references to randomised controlled trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Unpublished material</HEADING>
<P>We attempted to obtain details of unpublished and ongoing trials through correspondence with authors of identified studies, searching the metaRegister of Controlled Trials and contacting the pharmaceutical company Lipha Sante Pharmaceuticals.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Conference proceedings </HEADING>
<P>We scanned the abstracts from the following major stroke conference proceedings over the past five years (European Stroke Conference, American Heart Association Stroke Conference, International Stroke Conference).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse events</HEADING>
<P>We scanned all papers identified from searching the bibliographic databases and ongoing trials and research registers for adverse events or side effects.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Language</HEADING>
<P>We did not impose any language restrictions throughout this systematic review and we attempted to seek translations of non-English language papers if necessary.</P>
</SUBSECTION>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-09-03 19:41:24 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Study selection</HEADING>
<P>Two authors (JL-B and FB-H) independently screened the titles and abstracts of all publications obtained by the search to assess the eligibility of the article. If it was clear that the article did not refer to a randomised controlled trial of naftidrofuryl or one of its analogues, we excluded it. For all articles that could be an eligible trial we obtained the complete article, either by accessing the full text through the Internet or by requesting through our library. We then inspected the full-text articles to assess their relevance to this systematic review. Any disagreements were resolved through discussion with the review team. Excluded studies and reasons for exclusion are reported in the 'Characteristics of excluded studies' table.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of methodological quality</HEADING>
<P>Two authors (JL-B and FB-H) independently assessed the methodological quality of the included trials. The quality assessment included an evaluation of the following components for each included trial, since there is some evidence that these are associated with biased estimates of treatment effect (<LINK REF="REF-Juni-2001" TYPE="REFERENCE">Juni 2001</LINK>):<BR/>(1) the method of generation of the randomisation sequence;<BR/>(2) the method of allocation concealment (considered adequate if the assignment cannot be foreseen);<BR/>(3) who was blinded or not blinded (participants, clinicians, outcome assessors);<BR/>(4) how many participants were lost to follow up in each arm (split into post-randomisation exclusions and later losses if possible); and<BR/>(5) whether the participants were analysed in the groups to which they were originally randomised (intention to treat).</P>
<P>In addition, the quality assessment also included whether:<BR/>(1) a sample size calculation was declared;<BR/>(2) inclusion and exclusion criteria were defined;<BR/>(3) time to follow up was stated;<BR/>(4) baseline comparability of severity of age, gender, and time since ictus was stated;<BR/>(5) inclusion of a statement relating to conflict of interest was stated; and<BR/>(6) the statistical analysis was appropriate (this criterion was considered if the original data could not be extracted from the publication).</P>
<P>We have recorded this information in the 'Characteristics of included studies' table and a description of the quality of each study is given based on these components.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data extraction</HEADING>
<P>Two authors (JL-B and FB-H) performed data extraction independently and any differences were resolved through discussion with the review team. If possible, we obtained missing data from the trial authors. We used a data collection form in order to summarise the information from the trials. One author (JL-B) entered and checked the data. If available, we sought individual patient data from the original trialists, which were re-analysed using consistent statistical methods and the resulting group data used in preference to the published data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Analysis</HEADING>
<P>For studies with a similar type of intervention, for example oral naftidrofuryl, we performed a meta-analysis to calculate a weighted treatment effect across trials using a random-effects model (DerSimonian and Laird model). The results were expressed as odds ratios (OR) with 95% confidence intervals (CI) for dichotomous outcomes, and mean differences (MD) with 95% CI for continuous outcomes. We did not express the results as the number needed to treat due to non-significant findings.</P>
<P>We assessed heterogeneity between the trials using I squared (I<SUP>2</SUP>) (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>). If substantial heterogeneity (I<SUP>2</SUP> greater than 50%) existed between studies for the primary outcome, we explored reasons for the heterogeneity, such as disease severity, dosage and duration of treatment, type of stroke (ischaemia or haemorrhage) using subgroup analyses. We had planned to conduct sensitivity analyses to examine the effects of excluding studies with lower reported methodological quality but lack of data precluded this. If it was not possible to perform a meta-analysis, either due to too much heterogeneity (I<SUP>2 </SUP>&gt; 80%) or where there was a lack of evidence, we summarised the data for each trial.</P>
<P>We used individual patient data in preference to published data, if available. Data were expressed as OR with 95% CI for dichotomous outcomes. We had also planned to perform multivariate logistic regression models to assess the individual level effects of the ages of participants examined, stroke type (ischaemia or haemorrhage), route of administration (oral, intravenous), timing and length of follow up as described by the trialists, on the efficacy of naftidrofuryl in acute stroke, but the small number of trials identified and subsequently included in the review precluded this.</P>
<P>We dichotomised data relating to disability or dependency irrespective of scale used, (e.g. Barthel Index 0 to 55, modified Rankin score 3 to 5). If non-consistent cut offs were used across trials, we used the raw individual patient data to create consistent categories (e.g. Barthel Index 0 to 55, modified Rankin score 3 to 5). If more than one disability or dependency measurement scale was used within a trial, we used the most frequently used measurement scale across trials for the primary analysis. We had planned to conduct sensitivity analyses to examine the effects of the individual measurement scales but insufficient data precluded this. We defined deterioration as any worsening in severity of stroke within seven days post ictus, measured using a recognised and validated assessment (for example, the Scandinavian Neurological Stroke Scale).</P>
<P>We listed quasi-randomised and non-randomised controlled studies, but did not discuss these further. We described studies relating to adverse events qualitatively.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Other</HEADING>
<P>We attempted to contact trial authors for clarification if there was uncertainty.</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-09-03 19:43:57 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION>
<P>We sought the full text articles for a total of 24 studies identified by the search. Seventeen of these studies were excluded either due to not being randomised (<LINK REF="STD-Akopov-1996" TYPE="STUDY">Akopov 1996</LINK>; <LINK REF="STD-Capon-1990" TYPE="STUDY">Capon 1990</LINK>; <LINK REF="STD-Delwaide-1992" TYPE="STUDY">Delwaide 1992</LINK>; <LINK REF="STD-Kobayaski-1984" TYPE="STUDY">Kobayaski 1984</LINK>; <LINK REF="STD-Miyazaki-1992" TYPE="STUDY">Miyazaki 1992</LINK>; <LINK REF="STD-Otomo-1987" TYPE="STUDY">Otomo 1987</LINK>; <LINK REF="STD-Otomo-1991" TYPE="STUDY">Otomo 1991</LINK>; <LINK REF="STD-Robinson-1972" TYPE="STUDY">Robinson 1972</LINK>), having no comparison group (<LINK REF="STD-Chodkiewicz-1973" TYPE="STUDY">Chodkiewicz 1973</LINK>; <LINK REF="STD-Ishioka-1986" TYPE="STUDY">Ishioka 1986</LINK>; <LINK REF="STD-Nakano-1986" TYPE="STUDY">Nakano 1986</LINK>; <LINK REF="STD-Otomo-1986" TYPE="STUDY">Otomo 1986</LINK>), not assessing patients in the acute phase of stroke (<LINK REF="STD-Agnoli-1985" TYPE="STUDY">Agnoli 1985</LINK>; <LINK REF="STD-Ducarne-1986" TYPE="STUDY">Ducarne 1986</LINK>; <LINK REF="STD-Orgogozo-1998" TYPE="STUDY">Orgogozo 1998</LINK>), or presenting review data (<LINK REF="STD-Judge-1978" TYPE="STUDY">Judge 1978</LINK>; <LINK REF="STD-Steiner-1990" TYPE="STUDY">Steiner 1990</LINK>). One extra study, which included 39 participants, is currently awaiting assessment until a translation can be sought (<LINK REF="STD-Litomericky-1982" TYPE="STUDY">Litomericky 1982</LINK>). Thus, six randomised controlled trials were deemed eligible for inclusion in the systematic review (<LINK REF="STD-Admani-1978" TYPE="STUDY">Admani 1978</LINK>; <LINK REF="STD-Autret-1992" TYPE="STUDY">Autret 1992</LINK>; <LINK REF="STD-Busse-1985" TYPE="STUDY">Busse 1985</LINK>; <LINK REF="STD-Gray-1990" TYPE="STUDY">Gray 1990</LINK>; <LINK REF="STD-Steiner-1986" TYPE="STUDY">Steiner 1986</LINK>; <LINK REF="STD-Steiner-1996" TYPE="STUDY">Steiner 1996</LINK>). A total of 1274 participants were included in these trials. </P>
<P>All of the six included studies had been published and all, except one (<LINK REF="STD-Steiner-1986" TYPE="STUDY">Steiner 1986</LINK>), used a two-arm parallel groups design. <LINK REF="STD-Steiner-1986" TYPE="STUDY">Steiner 1986</LINK> used a three-arm parallel group design, comprising of a control group (inactive vehicles), and two active treatment groups. One active treatment group received naftidrofuryl for 10 days, and the other active treatment group consisted of participants who commenced treatment within 12 hours of stroke onset, and who were randomly allocated to a combination of active infusion and placebo capsules (n = 11). For the analyses in this review, wherever possible, the participants from the two active treatment groups were combined and analysed as a single active treatment group. Three studies used single centres (<LINK REF="STD-Admani-1978" TYPE="STUDY">Admani 1978</LINK>; <LINK REF="STD-Busse-1985" TYPE="STUDY">Busse 1985</LINK>; <LINK REF="STD-Steiner-1986" TYPE="STUDY">Steiner 1986</LINK>); one study used two centres (<LINK REF="STD-Gray-1990" TYPE="STUDY">Gray 1990</LINK>), and the remaining two studies used 9 and 18 centres, respectively (<LINK REF="STD-Autret-1992" TYPE="STUDY">Autret 1992</LINK>; <LINK REF="STD-Steiner-1996" TYPE="STUDY">Steiner 1996</LINK>). Naftidrofuryl was either administrated as naftidrofuryl oxalate (<LINK REF="STD-Autret-1992" TYPE="STUDY">Autret 1992</LINK>; <LINK REF="STD-Busse-1985" TYPE="STUDY">Busse 1985</LINK>; <LINK REF="STD-Gray-1990" TYPE="STUDY">Gray 1990</LINK>; <LINK REF="STD-Steiner-1986" TYPE="STUDY">Steiner 1986</LINK>), or as naftidrofuryl fumarate (LS 129) (<LINK REF="STD-Steiner-1996" TYPE="STUDY">Steiner 1996</LINK>). One study did not specify the type of naftidrofuryl used (<LINK REF="STD-Admani-1978" TYPE="STUDY">Admani 1978</LINK>). All studies used matching placebos as the control treatment. The following list shows the specific active treatment regimens and total number of participants used in the studies:</P>
<P>
<LINK REF="STD-Admani-1978" TYPE="STUDY">Admani 1978</LINK>: 600 mg capsule for four weeks, then 300 mg capsule for eight weeks (98 participants);<BR/>
<LINK REF="STD-Autret-1992" TYPE="STUDY">Autret 1992</LINK>: 400 mg intravenous (iv) infusion for seven days, then 600 mg tablets for six months (312 participants);<BR/>
<LINK REF="STD-Busse-1985" TYPE="STUDY">Busse 1985</LINK>: 800 mg iv infusion for 14 days, then 600 mg tablets for 10 weeks (41 participants);<BR/>
<LINK REF="STD-Gray-1990" TYPE="STUDY">Gray 1990</LINK>: 633 mg oral sustained release for 12 weeks (100 participants);<BR/>
<LINK REF="STD-Steiner-1986" TYPE="STUDY">Steiner 1986</LINK>: 600 mg iv infusion for 10 days, then 300 mg capsule for nine months (103 participants);<BR/>
<LINK REF="STD-Steiner-1996" TYPE="STUDY">Steiner 1996</LINK>: 633 mg iv infusion for seven days, then oral sustained release for six months (620 participants).</P>
<P>We did not identify any studies that assessed the effectiveness of an analogue of naftidrofuryl.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>The methods used in the six included trials are summarised in the 'Characteristics of included studies' table. The numbers of participants included in the studies ranged from 41 participants (<LINK REF="STD-Busse-1985" TYPE="STUDY">Busse 1985</LINK>) to 620 participants (<LINK REF="STD-Steiner-1996" TYPE="STUDY">Steiner 1996</LINK>). All of the six included trials were double blind. The method of randomisation was stated in four of the six included trials. The trials either used a previously drawn up randomised list based on blocks of six patients (<LINK REF="STD-Autret-1992" TYPE="STUDY">Autret 1992</LINK>), a numerical code (<LINK REF="STD-Admani-1978" TYPE="STUDY">Admani 1978</LINK>), stratification based on time from stroke onset, severity of stroke, age, sex, and affected side (<LINK REF="STD-Steiner-1986" TYPE="STUDY">Steiner 1986</LINK>), or a method similar to minimisation based on stratifying by age and stroke severity (<LINK REF="STD-Steiner-1996" TYPE="STUDY">Steiner 1996</LINK>). The other studies either reported that randomisation was performed by the pharmaceutical company involved in the trial (<LINK REF="STD-Gray-1990" TYPE="STUDY">Gray 1990</LINK>) or did not specify the method used (<LINK REF="STD-Busse-1985" TYPE="STUDY">Busse 1985</LINK>).</P>
<P>An adequate method of allocation concealment was reported in three trials (<LINK REF="STD-Gray-1990" TYPE="STUDY">Gray 1990</LINK>; <LINK REF="STD-Steiner-1986" TYPE="STUDY">Steiner 1986</LINK>; <LINK REF="STD-Steiner-1996" TYPE="STUDY">Steiner 1996</LINK>). The <LINK REF="STD-Gray-1990" TYPE="STUDY">Gray 1990</LINK> study used centralised allocation provided and held by the pharmaceutical company and pharmacies at the study hospitals. The two trials by Steiner and colleagues dispensed the treatments by a pharmacist according to next number in a computer-randomised list of company-pre packed pre-coded matching active or placebo materials (<LINK REF="STD-Steiner-1986" TYPE="STUDY">Steiner 1986</LINK>; <LINK REF="STD-Steiner-1996" TYPE="STUDY">Steiner 1996</LINK>).</P>
<P>Intention-to-treat (ITT) analyses were performed in three of the included trials (<LINK REF="STD-Admani-1978" TYPE="STUDY">Admani 1978</LINK>; <LINK REF="STD-Gray-1990" TYPE="STUDY">Gray 1990</LINK>; <LINK REF="STD-Steiner-1996" TYPE="STUDY">Steiner 1996</LINK>); the other trials withdrew participants post randomisation (<LINK REF="STD-Autret-1992" TYPE="STUDY">Autret 1992</LINK>; <LINK REF="STD-Busse-1985" TYPE="STUDY">Busse 1985</LINK>; <LINK REF="STD-Steiner-1986" TYPE="STUDY">Steiner 1986</LINK>). One study also presented <I>per protocol</I> analyses where participants were excluded mostly due to reasons relating to misdiagnosis of haemorrhage or non-compliance of treatment (<LINK REF="STD-Steiner-1996" TYPE="STUDY">Steiner 1996</LINK>). No side effects or safety concerns were reported in either the active or placebo treatments in two of the included trials (<LINK REF="STD-Gray-1990" TYPE="STUDY">Gray 1990</LINK>; <LINK REF="STD-Steiner-1996" TYPE="STUDY">Steiner 1996</LINK>). In the <LINK REF="STD-Admani-1978" TYPE="STUDY">Admani 1978</LINK> trial, minor side effects were reported in five of the naftidrofuryl-treated group and one participant in the placebo group; however none of these participants withdrew from treatment. Three participants were withdrawn from the <LINK REF="STD-Steiner-1986" TYPE="STUDY">Steiner 1986</LINK> trial, either due to side effects of naftidrofuryl (one participant), or due to technical failure of the intravenous infusion during the first 48 hours of treatment (one naftidrofuryl, one placebo), and six participants withdrew whilst on treatment in the <LINK REF="STD-Autret-1992" TYPE="STUDY">Autret 1992</LINK> trial (four in the naftidrofuryl group and two in the control group). In the <LINK REF="STD-Busse-1985" TYPE="STUDY">Busse 1985</LINK> trial, eight participants withdrew from treatment due to complications (four naftidrofuryl, four placebo).</P>
<P>A sample size calculation was only declared in one study (<LINK REF="STD-Gray-1990" TYPE="STUDY">Gray 1990</LINK>), which was based on using information obtained from previous studies of naftidrofuryl in acute stroke.</P>
<P>Detailed inclusion and exclusion criteria and information relating to the baseline comparability of participant characteristics between treatment groups were reported in all of the included studies. Participant characteristics relating to age, gender, and time since ictus (delay) were found to be balanced between treatment groups for all of the studies. Outcome measures were assessed at various time across the trials and ranged from within one week post randomisation (<LINK REF="STD-Steiner-1986" TYPE="STUDY">Steiner 1986</LINK>) to 26 weeks post randomisation (<LINK REF="STD-Autret-1992" TYPE="STUDY">Autret 1992</LINK>; <LINK REF="STD-Gray-1990" TYPE="STUDY">Gray 1990</LINK>). Two studies reported long-term follow up at one year (<LINK REF="STD-Steiner-1986" TYPE="STUDY">Steiner 1986</LINK>; <LINK REF="STD-Steiner-1996" TYPE="STUDY">Steiner 1996</LINK>). </P>
<P>Lipha Sante Pharmaceuticals were involved in two of the studies. One study declared that they provided funding for the trial (<LINK REF="STD-Steiner-1986" TYPE="STUDY">Steiner 1986</LINK>), and the other declared that they supplied capsules (<LINK REF="STD-Admani-1978" TYPE="STUDY">Admani 1978</LINK>), however it is unclear whether the pharmaceutical company had any involvement in the analyses and subsequent report relating to these two studies. The appropriateness of the statistical analyses used in the analysis of some of the outcomes within the published papers was assessed; the statistical techniques used for these outcomes were found to be appropriate to the type of data being analysed.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-09-03 19:43:57 +0100" MODIFIED_BY="[Empty name]">
<P>Summary data were extracted from two of the studies (<LINK REF="STD-Admani-1978" TYPE="STUDY">Admani 1978</LINK>; <LINK REF="STD-Busse-1985" TYPE="STUDY">Busse 1985</LINK>), the trialists from the remaining four studies provided the authors with individual patient data (<LINK REF="STD-Autret-1992" TYPE="STUDY">Autret 1992</LINK>; <LINK REF="STD-Gray-1990" TYPE="STUDY">Gray 1990</LINK>; <LINK REF="STD-Steiner-1986" TYPE="STUDY">Steiner 1986</LINK>; <LINK REF="STD-Steiner-1996" TYPE="STUDY">Steiner 1996</LINK>). Individual patient data were therefore available for most of the included patients (89%).</P>
<SUBSECTION>
<HEADING LEVEL="3">Primary outcome measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Comparison 01.01: Late death (at end of scheduled follow up)</HEADING>
<P>All of the six included studies reported late death at the end of the trial (<LINK REF="STD-Admani-1978" TYPE="STUDY">Admani 1978</LINK>; <LINK REF="STD-Autret-1992" TYPE="STUDY">Autret 1992</LINK>; <LINK REF="STD-Busse-1985" TYPE="STUDY">Busse 1985</LINK>; <LINK REF="STD-Gray-1990" TYPE="STUDY">Gray 1990</LINK>; <LINK REF="STD-Steiner-1986" TYPE="STUDY">Steiner 1986</LINK>; <LINK REF="STD-Steiner-1996" TYPE="STUDY">Steiner 1996</LINK>). A pooled analysis found no relationship between late death and naftidrofuryl use (OR 1.03, 95% CI 0.78 to 1.36). No heterogeneity was detected between the studies (I<SUP>2 </SUP>= 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison 01.02: Late death or disability or dependency (at end of scheduled follow up)</HEADING>
<P>Combined late death or disability or dependency at the end of the trial was assessed in only three studies (<LINK REF="STD-Busse-1985" TYPE="STUDY">Busse 1985</LINK>; <LINK REF="STD-Steiner-1986" TYPE="STUDY">Steiner 1986</LINK>; <LINK REF="STD-Steiner-1996" TYPE="STUDY">Steiner 1996</LINK>). A pooled analysis of these studies found no significant difference in the odds of death in the naftidrofuryl group as compared with the placebo group (OR 0.94, 95% CI 0.70 to 1.26). No heterogeneity was detected between the studies (I<SUP>2 </SUP>= 0%).</P>
<P>A measure of disability or dependency at the end of the trial was assessed in all of the included studies (<LINK REF="STD-Admani-1978" TYPE="STUDY">Admani 1978</LINK>; <LINK REF="STD-Autret-1992" TYPE="STUDY">Autret 1992</LINK>; <LINK REF="STD-Busse-1985" TYPE="STUDY">Busse 1985</LINK>; <LINK REF="STD-Gray-1990" TYPE="STUDY">Gray 1990</LINK>; <LINK REF="STD-Steiner-1986" TYPE="STUDY">Steiner 1986</LINK>; <LINK REF="STD-Steiner-1996" TYPE="STUDY">Steiner 1996</LINK>). The trial by <LINK REF="STD-Steiner-1986" TYPE="STUDY">Steiner 1986</LINK> reported significant differences in functional recovery (similar to the modified Rankin Score) at the end of the trial in favour of the naftidrofuryl group (MD 0.19 points, P &lt; 0.05, Wilcoxon two sample test); however the <LINK REF="STD-Steiner-1996" TYPE="STUDY">Steiner 1996</LINK> did not present findings for the outcome. The trial by <LINK REF="STD-Admani-1978" TYPE="STUDY">Admani 1978</LINK> reported that there was a significant difference in the overall functional scores (which included assessments of power, sensation, cerebellar functions, speech, sphincter controls, mental functions, activities of daily living and general functions) at the end of trial (MD 9.83 points, P &lt; 0.05, Mann Whitney U test). The trial by <LINK REF="STD-Autret-1992" TYPE="STUDY">Autret 1992</LINK> reported no significant difference in the daily activities score from baseline to week 26 between the treatment groups. Two studies also assessed recovery using limb function assessments (<LINK REF="STD-Autret-1992" TYPE="STUDY">Autret 1992</LINK>; <LINK REF="STD-Gray-1990" TYPE="STUDY">Gray 1990</LINK>). The study by <LINK REF="STD-Autret-1992" TYPE="STUDY">Autret 1992</LINK> reported a significant difference in combined upper and lower limb function at the end of trial (MD 4.12 points, P &lt; 0.01, t test), however, the other study found no significant difference in either upper limb or lower limb (<LINK REF="STD-Gray-1990" TYPE="STUDY">Gray 1990</LINK>). The trial by <LINK REF="STD-Busse-1985" TYPE="STUDY">Busse 1985</LINK> found no significant difference in the combined neurological and functional score between the treatment groups (P = 0.175, Wilcoxon signed rank test).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcome measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Comparison 02.01: Early death (within one month of randomisation)</HEADING>
<P>Three studies reported early death, either within 28 days (<LINK REF="STD-Gray-1990" TYPE="STUDY">Gray 1990</LINK>) or 30 days (<LINK REF="STD-Autret-1992" TYPE="STUDY">Autret 1992</LINK>; <LINK REF="STD-Busse-1985" TYPE="STUDY">Busse 1985</LINK>) post randomisation. A pooled analysis of these studies showed a 10% non-significant increase in the odds of early death in the naftidrofuryl group as compared with the placebo group (OR 1.10, 95% CI 0.63 to 1.91).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Early death or deterioration (within one month of randomisation)</HEADING>
<P>The combined outcome of early death or deterioration was not reported in any of the included studies, except for the trial by <LINK REF="STD-Busse-1985" TYPE="STUDY">Busse 1985</LINK>; however data for this study could not be extracted due to lack of clarity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Quality of life (at end of scheduled follow up)</HEADING>
<P>Quality of life was not reported in any of the included studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparisons 02.02 and 02.03: Length of stay </HEADING>
<P>Four trials reported length of stay in hospital (<LINK REF="STD-Admani-1978" TYPE="STUDY">Admani 1978</LINK>; <LINK REF="STD-Autret-1992" TYPE="STUDY">Autret 1992</LINK>; <LINK REF="STD-Steiner-1986" TYPE="STUDY">Steiner 1986</LINK>; <LINK REF="STD-Steiner-1996" TYPE="STUDY">Steiner 1996</LINK>).<B> </B>Two of these trials (<LINK REF="STD-Admani-1978" TYPE="STUDY">Admani 1978</LINK>; <LINK REF="STD-Autret-1992" TYPE="STUDY">Autret 1992</LINK>) reported sufficient information to allow for inclusion into a meta-analysis (Comparison 02/02), however a pooled analysis was not performed since extreme levels of heterogeneity were detected between the trials (I<SUP>2 </SUP>= 89%). Both of these trials reported shorter lengths of stay for the naftidrofuryl group as compared with the placebo group. <LINK REF="STD-Steiner-1996" TYPE="STUDY">Steiner 1996</LINK> reported a significantly shorter time to discharge in patients randomised to naftidrofuryl as compared with placebo, by approximately 24 days (P &lt; 0.001, log-rank test, ITT analysis). Inpatient days were significantly shorter, by approximately 67 days, in the naftidrofuryl group as compared with the placebo group in the <LINK REF="STD-Steiner-1986" TYPE="STUDY">Steiner 1986</LINK> study (P &lt; 0.02, t test). Three studies also assessed the numbers of participants discharged at the end of trial (<LINK REF="STD-Admani-1978" TYPE="STUDY">Admani 1978</LINK>; <LINK REF="STD-Gray-1990" TYPE="STUDY">Gray 1990</LINK>; <LINK REF="STD-Steiner-1986" TYPE="STUDY">Steiner 1986</LINK>). A pooled analysis of these studies found no difference in the proportion of participants discharged between the treatment groups (OR 1.04, 95% CI 0.64 to 1.69) (Comparison 02/03). Low levels of heterogeneity were seen between the trials (I<SUP>2 </SUP>= 3%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Stroke recurrence (at any time during scheduled follow up)</HEADING>
<P>Stroke recurrence was not reported in any of the included studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Discharge site (death, institution, home)</HEADING>
<P>A comparison of the discharge site was not reported in any of the included studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparisons 02.04, 02.05, and 02.06: Blood pressure </HEADING>
<P>Baseline blood pressure measurements were taken in four of the included trials (<LINK REF="STD-Autret-1992" TYPE="STUDY">Autret 1992</LINK>; <LINK REF="STD-Gray-1990" TYPE="STUDY">Gray 1990</LINK>; <LINK REF="STD-Steiner-1986" TYPE="STUDY">Steiner 1986</LINK>; <LINK REF="STD-Steiner-1996" TYPE="STUDY">Steiner 1996</LINK>), however, on-treatment blood pressure measurements were only recorded in two trials (<LINK REF="STD-Steiner-1986" TYPE="STUDY">Steiner 1986</LINK>; <LINK REF="STD-Steiner-1996" TYPE="STUDY">Steiner 1996</LINK>). Systolic, diastolic and mean arterial blood pressures were measured at 24 and 48 hours on treatment in both trials. A pooled analysis indicated no significant difference in blood pressure at 24 (MD 1.50 mm Hg, 95% CI -2.02 to 5.02) or 48 (MD -1.54 mm Hg, 95% CI -9.99 to 6.90) hours on treatment (Comparison 02/04). Similar pooled results were seen for diastolic blood pressure (24 hours MD 1.16 mm Hg, 95% CI -1.5 to 3.82; 48 hours MD -0.88 mm Hg, 95% CI -5.42 to 3.67) (Comparison 02/05), and mean arterial blood pressure (24 hours MD 1.41 mm Hg, 95% CI -0.79 to 3.62; 48 hours MD -1.12 mm hg, 95% CI -7.20 to 4.96) (Comparison 02/06). Moderate to high levels of heterogeneity were seen between the study estimates for all of the blood pressure measurements at 48 hours on treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison 02.07: Serious adverse events (requiring withdrawal of the treatment)</HEADING>
<P>Three studies reported serious adverse events which required withdrawal of allocated treatment (<LINK REF="STD-Autret-1992" TYPE="STUDY">Autret 1992</LINK>; <LINK REF="STD-Busse-1985" TYPE="STUDY">Busse 1985</LINK>; <LINK REF="STD-Steiner-1986" TYPE="STUDY">Steiner 1986</LINK>). During the intravenous phase of the <LINK REF="STD-Autret-1992" TYPE="STUDY">Autret 1992</LINK> trial several participants experienced venous irritation which resulted in six participants withdrawing from treatment (four naftidrofuryl, two placebo). In the <LINK REF="STD-Steiner-1986" TYPE="STUDY">Steiner 1986</LINK> trial one participant in the naftidrofuryl group developed an allergic cutaneous maculopapular rash which necessitated stopping treatment during the intravenous phase. The study medication was stopped for eight cases (four naftidrofuryl, four placebo) in the <LINK REF="STD-Busse-1985" TYPE="STUDY">Busse 1985</LINK> trial because of complications relating to haemorrhage, kidney or heart insufficiency, pulmonary oedema, gastrointestinal bleeding or cardiac infarction. No serious side effects or safety concerns were reported in the other trials (<LINK REF="STD-Gray-1990" TYPE="STUDY">Gray 1990</LINK>; <LINK REF="STD-Steiner-1996" TYPE="STUDY">Steiner 1996</LINK>). A pooled analysis of these results indicated no significant difference in the risk of serious adverse events in the naftidrofuryl group as compared with the placebo group (OR 1.52, 95% CI 0.53 to 4.35).
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison 02.08: Minor adverse events (not requiring withdrawal of the treatment)</HEADING>
<P>Three trials reported minor adverse events (<LINK REF="STD-Admani-1978" TYPE="STUDY">Admani 1978</LINK>; <LINK REF="STD-Autret-1992" TYPE="STUDY">Autret 1992</LINK>; <LINK REF="STD-Steiner-1986" TYPE="STUDY">Steiner 1986</LINK>). Non-specific minor side effects were noted in five naftidrofuryl-treated participants and one placebo-group participant, however none of these events resulted in withdrawal from treatment (<LINK REF="STD-Admani-1978" TYPE="STUDY">Admani 1978</LINK>). Venous irritation in 17 naftidrofuryl and 11 placebo participants was reported in the intravenous phase of the <LINK REF="STD-Autret-1992" TYPE="STUDY">Autret 1992</LINK>, various symptoms were also reported during the oral phase of this trial which included gastric pain, constipation, sensation of vertigo, drowsiness, insomnia, meteorism, and pruritis. In the <LINK REF="STD-Steiner-1986" TYPE="STUDY">Steiner 1986</LINK> trial, one naftidrofuryl-treated participant suffered cutaneous ulceration at the infusion site, but went on to complete treatment. No minor adverse events were reported in the other trials (<LINK REF="STD-Busse-1985" TYPE="STUDY">Busse 1985</LINK>; <LINK REF="STD-Gray-1990" TYPE="STUDY">Gray 1990</LINK>; <LINK REF="STD-Steiner-1996" TYPE="STUDY">Steiner 1996</LINK>). A pooled analysis of these results indicated a trend towards a doubling in risk of a minor adverse event in the naftidrofuryl group as compared with the placebo group (OR 1.99, 95% CI 0.96 to 4.11, P = 0.06).<BR/>
</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>This systematic review has shown that naftidrofuryl given as a treatment in the acute stage of stroke does not significantly increase or decrease the risk of mortality or combined death or dependency/disability. All of the studies reported death and several studies reported disability/dependency; however very few trials (<LINK REF="STD-Busse-1985" TYPE="STUDY">Busse 1985</LINK>; <LINK REF="STD-Steiner-1986" TYPE="STUDY">Steiner 1986</LINK>; <LINK REF="STD-Steiner-1996" TYPE="STUDY">Steiner 1996</LINK>) reported the combined outcome of death or disability/dependency, therefore it is likely that the pooled results for the combined outcome is not generalisable. Although disability/dependency as a single outcome measure was not specified <I>a priori</I> in this review, all of the studies reported the outcome. Significant improvements from individual trials' results were seen for functional recovery, however disparate results were seen from the trials which assessed limb function, and no significant effect of naftidrofuryl was seen on the combined outcome of neurological and function outcome. A pooled analysis of these studies was not performed since most of the studies only presented P values from their own analyses. However, these findings need to be interpreted with caution since the outcome only assessed the effect of naftidrofuryl in survivors. Pooled results showed naftidrofuryl had no significant effect on systolic, diastolic or mean arterial blood pressure at 24 hours and 48 hours whilst on treatment. No trials reported the effects of naftidrofuryl on the risk of early death or deterioration, quality of life, stroke recurrence, or discharge site.</P>
<P>However, there is some evidence that naftidrofuryl might have an effect on shortening length of stay in hospital, but a meta-analysis of this outcome using data from the two studies with sufficient data was not possible due to high levels of heterogeneity between the study estimates. However, when assessing the significance of the findings from each of the four studies which reported the outcome, three of the studies found significantly shorter durations of hospital stay, and the other study found a borderline significant reduction in length of hospital stay. Although this is a secondary outcome of the review and emphasis of these findings should not shadow the non-significant findings of the primary outcome, one could hypothesise that a pooled result of all of these four studies might yield a significant reduction in hospital stay. </P>
<P>Several studies reported serious adverse events which necessitated withdrawal of study medication; however, there did not seem to be a disproportionate number of serious adverse events in the naftidrofuryl group as compared with the placebo group. Very few minor adverse events were reported in the trials; however, in the <LINK REF="STD-Autret-1992" TYPE="STUDY">Autret 1992</LINK> trial several naftidrofuryl and placebo participants experienced venous irritation related to the method of administration. </P>
<P>A major factor that needs to be addressed relates to the small number of randomised controlled trials that have been conducted in the acute stage of stroke, defined in this review as within seven days of stroke onset. Whilst several non-randomised double-blinded studies have been conducted which have shown favourable results of naftidrofuryl, the findings from non-randomised controlled trials needs to be interpreted with caution due to the inherent biases with such a design. Another limitation of the review relates to the methodological quality of the included studies: whilst the majority of the studies gave sufficient details eluding to adequate methods of randomisation (<LINK REF="STD-Admani-1978" TYPE="STUDY">Admani 1978</LINK>; <LINK REF="STD-Autret-1992" TYPE="STUDY">Autret 1992</LINK>; <LINK REF="STD-Steiner-1986" TYPE="STUDY">Steiner 1986</LINK>; <LINK REF="STD-Steiner-1996" TYPE="STUDY">Steiner 1996</LINK>), only one study gave details relating to allocation concealment (<LINK REF="STD-Gray-1990" TYPE="STUDY">Gray 1990</LINK>). Concealment of allocation is regarded as one of the primary components of methodological quality (<LINK REF="REF-Juni-2001" TYPE="REFERENCE">Juni 2001</LINK>), and therefore the remaining five studies were deemed to have low methodological quality since they did not report this component (<LINK REF="STD-Admani-1978" TYPE="STUDY">Admani 1978</LINK>; <LINK REF="STD-Autret-1992" TYPE="STUDY">Autret 1992</LINK>; <LINK REF="STD-Busse-1985" TYPE="STUDY">Busse 1985</LINK>; <LINK REF="STD-Steiner-1986" TYPE="STUDY">Steiner 1986</LINK>; <LINK REF="STD-Steiner-1996" TYPE="STUDY">Steiner 1996</LINK>).</P>
<P>Therefore, there is not enough evidence to support the use of naftidrofuryl in the treatment of acute ischaemic or haemorrhagic stroke.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>There appears to be little evidence for using naftidrofuryl as a treatment in the acute stage of stroke. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Although only six randomised controlled trials were identified in this review, there is little evidence to conduct further studies using naftidrofuryl in the treatment of acute stroke.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We would like to thank the authors of the included trials who provided individual patient data (<LINK REF="STD-Autret-1992" TYPE="STUDY">Autret 1992</LINK>; <LINK REF="STD-Gray-1990" TYPE="STUDY">Gray 1990</LINK>; <LINK REF="STD-Steiner-1986" TYPE="STUDY">Steiner 1986</LINK>; <LINK REF="STD-Steiner-1996" TYPE="STUDY">Steiner 1996</LINK>). We are grateful to the Editorial Board of the Cochrane Stroke Group and external peer reviewers for their comments on the protocol and review. </P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>Dr Tim Steiner was the chief principal investigator for two of the trials included in the review. All the analyses and their interpretation reflect the opinions of the authors; no pharmaceutical company was involved in the analysis or interpretation of data, or in the writing of this review.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-09-03 19:45:44 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Protocol and review written by Jo Leonardi-Bee, Fiona Bath-Hextall, and Tim Steiner.</LI>
<LI>Searches by Jo Leonardi-Bee and Fiona Bath-Hextall.</LI>
<LI>Decision on including trials by Jo Leonardi-Bee and Fiona Bath-Hextall.</LI>
<LI>Assessment of methodological quality by Jo Leonardi-Bee and Fiona Bath-Hextall.</LI>
<LI>Data entry by Jo Leonardi-Bee and Fiona Bath-Hextall.</LI>
</UL>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-09-03 19:50:10 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2008-09-03 19:48:25 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2008-09-03 19:46:40 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Admani-1978" MODIFIED="2008-09-03 19:46:14 +0100" MODIFIED_BY="[Empty name]" NAME="Admani 1978" YEAR="1978">
<REFERENCE MODIFIED="2008-09-03 19:46:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Admani AK</AU>
<TI>New approaches to treatment of recent stroke</TI>
<SO>BMJ</SO>
<YR>1978</YR>
<VL>2</VL>
<PG>1678-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Autret-1992" MODIFIED="2008-09-03 19:46:20 +0100" MODIFIED_BY="[Empty name]" NAME="Autret 1992" YEAR="1992">
<REFERENCE MODIFIED="2008-09-03 19:46:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Autret A, Lehert P, Mosnier M</AU>
<TI>Study of naftidrofuryl in cerebral ischaemic accidents</TI>
<TO>Etude du naftidrofuryl dans les accidents ischemiques cerebraux</TO>
<SO>Psychologie Medicale</SO>
<YR>1992</YR>
<VL>24</VL>
<NO>1</NO>
<PG>103-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Busse-1985" MODIFIED="2008-09-03 19:46:26 +0100" MODIFIED_BY="[Empty name]" NAME="Busse 1985" YEAR="1985">
<REFERENCE MODIFIED="2008-09-03 19:46:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Busse O, Hornig CR, Agnoli AL</AU>
<TI>Treatment of the ischemic cerebral infarction with naftidrofuryl</TI>
<TO>Behandlung des ischamischen hirninfarktes mit naftidrofuryl</TO>
<SO>Therapiewoche</SO>
<YR>1985</YR>
<VL>35</VL>
<NO>37</NO>
<PG>4147-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Gray-1990" MODIFIED="2008-09-03 19:46:30 +0100" MODIFIED_BY="[Empty name]" NAME="Gray 1990" YEAR="1990">
<REFERENCE MODIFIED="2008-09-03 19:46:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gray CS, French JM, Venables GS, Cartlidge NEF, James OFW, Bates D</AU>
<TI>A randomized double-blind controlled trial of naftidrofuryl in acute stroke</TI>
<SO>Age and Ageing</SO>
<YR>1990</YR>
<VL>19</VL>
<PG>356-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Steiner-1986" NAME="Steiner 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Steiner TJ, Rose C</AU>
<TI>Randomized double-blind placebo-controlled clinical trial of naftidrofuryl in hemiparetic CT-proven acute cerebral hemisphere infarction</TI>
<SO>Royal Society of Medicine Series. International Congress and Symposium Series</SO>
<YR>1986</YR>
<PG>85-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Steiner TJ, Rose FC</AU>
<TI>Towards a model stroke trial. The single-centre naftidrofuryl study</TI>
<SO>Neuroepidemiology</SO>
<YR>1986</YR>
<VL>5</VL>
<NO>3</NO>
<PG>121-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steiner TJ</AU>
<TI>Naftidrofuryl in the treatment of recent stroke. Results of a controlled clinical trial</TI>
<SO>VASA</SO>
<YR>1988</YR>
<VL>Suppl 24</VL>
<PG>44-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Steiner-1996" MODIFIED="2008-09-03 19:46:40 +0100" MODIFIED_BY="[Empty name]" NAME="Steiner 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-09-03 19:46:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steiner TJ, Kjellstrom T, Sanders EACM, Olsson J-E, MacWalter RS, Park DM, et al</AU>
<TI>Naftidrofuryl in acute cerebral hemisphere infarction (ACHI). Principal results of the PRISTINE study</TI>
<SO>Stroke</SO>
<YR>1996</YR>
<VL>27</VL>
<NO>1</NO>
<PG>163</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-09-03 19:48:21 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Agnoli-1985" MODIFIED="2008-09-03 19:46:46 +0100" MODIFIED_BY="[Empty name]" NAME="Agnoli 1985" YEAR="1985">
<REFERENCE MODIFIED="2008-09-03 19:46:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Agnoli A, Martucci N, Manna V</AU>
<TI>Quantitative EEG as a tool in neuropharmacological studies: the effect of naftidrofuryl in chronic cerebrovascular diseases (CCVD)</TI>
<SO>Current Therapeutic Research</SO>
<YR>1985</YR>
<VL>37</VL>
<NO>3</NO>
<PG>387-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Akopov-1996" MODIFIED="2008-09-03 19:46:49 +0100" MODIFIED_BY="[Empty name]" NAME="Akopov 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-09-03 19:46:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Akopov SE, Darbinian VZh, Ovanesian GO</AU>
<TI>The investigation of blood filterability and its correction with naftidrofuril in patients with cerebrovascular diseases</TI>
<SO>Zhurnal Nevropatologii Psikhiatrii Imeni S-S-Korsakova</SO>
<YR>1996</YR>
<VL>96</VL>
<NO>1</NO>
<PG>99-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Capon-1990" MODIFIED="2008-09-03 19:46:55 +0100" MODIFIED_BY="[Empty name]" NAME="Capon 1990" YEAR="1990">
<REFERENCE MODIFIED="2008-09-03 19:46:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Capon A, Lehert P, Opsomer L</AU>
<TI>Naftidrofuryl in the treatment of subacute stroke</TI>
<SO>Journal of Cardiovascular Pharmacology</SO>
<YR>1990</YR>
<VL>16(Suppl 3)</VL>
<PG>S62-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chodkiewicz-1973" MODIFIED="2008-09-03 19:46:58 +0100" MODIFIED_BY="[Empty name]" NAME="Chodkiewicz 1973" YEAR="1973">
<REFERENCE MODIFIED="2008-09-03 19:46:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chodkiewicz J-P, Visot A, Rivierez M, Conegero E</AU>
<TI>Clinical trials of Praxilene in a neurosurgical department</TI>
<TO>Essai Clinique du Praxilene en milieu neurochirurgical</TO>
<SO>Therapeutique</SO>
<YR>1973</YR>
<VL>49</VL>
<NO>9</NO>
<PG>567-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Delwaide-1992" MODIFIED="2008-09-03 19:47:02 +0100" MODIFIED_BY="[Empty name]" NAME="Delwaide 1992" YEAR="1992">
<REFERENCE MODIFIED="2008-09-03 19:47:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Delwaide PJ, De Pasqua V, Lehert P, D'Hodge R</AU>
<TI>Naftidrofuryl and quantified EEG of patients with ischemic stroke</TI>
<SO>Journal of Stroke and Cerebrovascular Diseases</SO>
<YR>1992</YR>
<VL>2(Suppl 1)</VL>
<PG>S111 (Abstract PO-D45)</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ducarne-1986" MODIFIED="2008-09-03 19:47:07 +0100" MODIFIED_BY="[Empty name]" NAME="Ducarne 1986" YEAR="1986">
<REFERENCE MODIFIED="2008-09-03 19:47:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ducarne H</AU>
<TI>Evaluation of a vasoactive substance, naftidrofuryl during the rehabilitation phase after an ischaemic insult</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>1986</YR>
<VL>10</VL>
<NO>1</NO>
<PG>58-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ishioka-1986" MODIFIED="2008-09-03 19:47:18 +0100" MODIFIED_BY="[Empty name]" NAME="Ishioka 1986" YEAR="1986">
<REFERENCE MODIFIED="2008-09-03 19:47:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ishioka T</AU>
<TI>Beneficial and adverse effects of LS-121 on cerebrovascular disturbances</TI>
<SO>Therapeutic Research</SO>
<YR>1986</YR>
<VL>4</VL>
<NO>4</NO>
<PG>803-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Judge-1978" MODIFIED="2008-09-03 19:47:21 +0100" MODIFIED_BY="[Empty name]" NAME="Judge 1978" YEAR="1978">
<REFERENCE MODIFIED="2008-09-03 19:47:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Judge TG</AU>
<TI>The therapeutic uses of naftidrofuryl (Praxilene) - cerebrovascular disease</TI>
<SO>Scottish Medical Journal</SO>
<YR>1978</YR>
<VL>23</VL>
<PG>43-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kobayaski-1984" MODIFIED="2008-09-03 19:47:28 +0100" MODIFIED_BY="[Empty name]" NAME="Kobayaski 1984" YEAR="1984">
<REFERENCE MODIFIED="2008-09-03 19:47:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kobayashi S, Yamaguchi S, Katsube T, Okada K, Kitani M, Murao M, et al</AU>
<TI>Effects of naftidrofuryl on the time course of the regional cerebral blood flow in acute ischemic stroke</TI>
<SO>Arzneimittel-Forschung</SO>
<YR>1984</YR>
<VL>34</VL>
<NO>11</NO>
<PG>1580-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miyazaki-1992" MODIFIED="2008-09-03 19:47:34 +0100" MODIFIED_BY="[Empty name]" NAME="Miyazaki 1992" YEAR="1992">
<REFERENCE MODIFIED="2008-09-03 19:47:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miyazaki M</AU>
<TI>Cerebrovascular action of naftidrofuryl oxalate from the elderly suffering from ischemic cerebrovascular diseases</TI>
<SO>Therapeutic Research</SO>
<YR>1992</YR>
<VL>13</VL>
<NO>9</NO>
<PG>193-201</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nakano-1986" MODIFIED="2008-09-03 19:47:46 +0100" MODIFIED_BY="[Empty name]" NAME="Nakano 1986" YEAR="1986">
<REFERENCE MODIFIED="2008-09-03 19:47:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nakano Y, Ishioka T</AU>
<TI>Efficacy of 200mg LS-121 (Naftidrofuryl) intravenous drip infusion against cerebrovascular disorders and investigation of its side effects</TI>
<SO>Therapeutic Research</SO>
<YR>1986</YR>
<VL>4</VL>
<NO>3</NO>
<PG>557-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Orgogozo-1998" MODIFIED="2008-09-03 19:47:51 +0100" MODIFIED_BY="[Empty name]" NAME="Orgogozo 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-09-03 19:47:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Orgogozo JM, Lehert Ph, Mosnier M</AU>
<TI>Effect of oral naftidrofuryl on ischemic stroke recovery in a multicenter, double-blind, placebo controlled study</TI>
<SO>Semaine des Hopitaux</SO>
<YR>1998</YR>
<VL>74</VL>
<NO>23-26</NO>
<PG>997-1002</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Otomo-1986" MODIFIED="2008-09-03 19:47:56 +0100" MODIFIED_BY="[Empty name]" NAME="Otomo 1986" YEAR="1986">
<REFERENCE MODIFIED="2008-09-03 19:47:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Otomo E</AU>
<TI>Nationwide long-term administration test using LS-121 against cerebrovascular disorders</TI>
<SO>Therapeutic Research</SO>
<YR>1986</YR>
<VL>4</VL>
<NO>5</NO>
<PG>1101-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Otomo-1987" MODIFIED="2008-09-03 19:48:01 +0100" MODIFIED_BY="[Empty name]" NAME="Otomo 1987" YEAR="1987">
<REFERENCE MODIFIED="2008-09-03 19:48:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Otomo E</AU>
<TI>Clinical evaluation of LS-121 injection in the treatment of cerebral infarction and cerebral haemorrhage in acute and subacute stages - multicenter double-blind study with placebo as the control drug</TI>
<SO>Clinical Evaluation</SO>
<YR>1987</YR>
<VL>15</VL>
<PG>107-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Otomo-1991" MODIFIED="2008-09-03 19:48:08 +0100" MODIFIED_BY="[Empty name]" NAME="Otomo 1991" YEAR="1991">
<REFERENCE MODIFIED="2008-09-03 19:48:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Otomo E</AU>
<TI>Clinical evaluation of LS-121 capsule - double blind study for determination of the optimum dose</TI>
<SO>Therapeutic Research</SO>
<YR>1991</YR>
<VL>12</VL>
<NO>5</NO>
<PG>415-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robinson-1972" MODIFIED="2008-09-03 19:48:16 +0100" MODIFIED_BY="[Empty name]" NAME="Robinson 1972" YEAR="1972">
<REFERENCE MODIFIED="2008-09-03 19:48:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Robinson K</AU>
<TI>A double-blind clinical trial of naftidrofuryl in cerebral vascular disorders</TI>
<SO>Medical Digest</SO>
<YR>1972</YR>
<VL>17</VL>
<NO>12</NO>
<PG>50-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steiner-1990" MODIFIED="2008-09-03 19:48:21 +0100" MODIFIED_BY="[Empty name]" NAME="Steiner 1990" YEAR="1990">
<REFERENCE MODIFIED="2008-09-03 19:48:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steiner TJ</AU>
<TI>Naftidrofuryl after acute stroke: a review and a hypothesis</TI>
<SO>Journal of Cardiovascular Pharmacology</SO>
<YR>1990</YR>
<VL>16(Suppl 3)</VL>
<PG>S58-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2008-09-03 19:48:25 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Litomericky-1982" MODIFIED="2008-09-03 19:48:25 +0100" MODIFIED_BY="[Empty name]" NAME="Litomericky 1982" YEAR="1982">
<REFERENCE MODIFIED="2008-09-03 19:48:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Litomericky S, Smolenova L, Traubner P, Simoni M, Slukova J, Belan P, et al</AU>
<TI>The effect of dusodril retard and complamin retard on the cerebrovascular diseases in the elderly</TI>
<SO>Farmaceuticky Obzor</SO>
<YR>1982</YR>
<VL>51</VL>
<NO>7</NO>
<PG>309-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-09-03 19:50:10 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-09-03 19:50:10 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-BASC-2000" MODIFIED="2008-09-03 19:50:10 +0100" MODIFIED_BY="[Empty name]" NAME="BASC 2000" TYPE="COCHRANE_REVIEW">
<AU>The Blood pressure in Acute Stroke Collaboration (BASC)</AU>
<TI>Vasoactive drugs for acute stroke</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-09-03 19:50:10 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-03 19:50:10 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="Art. No.: CD002839. DOI: 10.1002/14651858.CD002839"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Davies-1988" NAME="Davies 1988" TYPE="JOURNAL_ARTICLE">
<AU>Davies PTG, Steiner TJ</AU>
<TI>Naftidrofuryl fumarate on human platelet behaviour and evidence for a selective inhibition of 5-HT2 receptors</TI>
<SO>New Trends in Clinical Neuropharmacology</SO>
<YR>1988</YR>
<VL>11</VL>
<PG>13-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2002" NAME="Higgins 2002" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG</AU>
<TI>Quantifying heterogeneity in a meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>1539-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jagroop-2000" NAME="Jagroop 2000" TYPE="JOURNAL_ARTICLE">
<AU>Jagroop IA, Mikhailidis DP</AU>
<TI>Effect of endothelin-1 on human platelet shape change: reversal of activiation by naftidrofuryl</TI>
<SO>Platelets</SO>
<YR>2000</YR>
<VL>11</VL>
<NO>5</NO>
<PG>272-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Juni-2001" NAME="Juni 2001" TYPE="JOURNAL_ARTICLE">
<AU>Juni P, Altman DG, Egger M</AU>
<TI>Systematic reviews in health care: assessing the quality of randomised controlled trials</TI>
<SO>BMJ</SO>
<YR>2001</YR>
<VL>323</VL>
<PG>42-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leonardi_x002d_Bee-2002" NAME="Leonardi-Bee 2002" TYPE="JOURNAL_ARTICLE">
<AU>Leonardi-Bee J, Bath PMW, Phillips SJ, Sandercock PAG, for the IST Collaborative Group</AU>
<TI>Blood pressure and clinical outcomes in the International Stroke Trial</TI>
<SO>Stroke</SO>
<YR>2002</YR>
<VL>33</VL>
<NO>5</NO>
<PG>1315-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leponcin-1982" NAME="Leponcin 1982" TYPE="JOURNAL_ARTICLE">
<AU>Leponcin-Lafitte M, Grosdemouge C, Roy-Billon C, Duterte D, Rapin JR</AU>
<TI>Effects of naftidrofuryl on cerebral hemodynamics, metabolism and function after a retracted ischaemia</TI>
<SO>Archives Internationales de Pharmacodynamie et de Therapie</SO>
<YR>1982</YR>
<VL>260</VL>
<PG>218-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maloteaux-1986" NAME="Maloteaux 1986" TYPE="JOURNAL_ARTICLE">
<AU>Maloteaux JM</AU>
<TI>Biochemical and physiological evidences for antiserotonergic properties of naftidrofuryl</TI>
<SO>Arzneitmittelforschung</SO>
<YR>1986</YR>
<VL>36</VL>
<PG>1194-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Meynaud-1973" NAME="Meynaud 1973" TYPE="JOURNAL_ARTICLE">
<AU>Meynaud A, Grand M, Fontaine L</AU>
<TI>Effect of naftidrofuryl upon energy metabolism of the brain</TI>
<SO>Arzneitmittelforschung</SO>
<YR>1973</YR>
<VL>23</VL>
<PG>1431</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Meynaud-1975" NAME="Meynaud 1975" TYPE="JOURNAL_ARTICLE">
<AU>Meynaud A, Grand A, Belleville M, Fontaine L</AU>
<TI>Effect of naftidrofuryl on cerebral energy metabolism in mice. 2nd part</TI>
<TO>Effet du naftidrofuryl sur le metabolisme energetique cerebral chez la souris. Deuxieeme partie</TO>
<SO>Therapie</SO>
<YR>1975</YR>
<VL>30</VL>
<PG>777</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sandercock-1992" NAME="Sandercock 1992" TYPE="JOURNAL_ARTICLE">
<AU>Sandercock P, Willems H</AU>
<TI>Medical treatment of acute ischaemic stroke</TI>
<SO>Lancet</SO>
<YR>1992</YR>
<VL>339</VL>
<PG>537-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yesavage-1982" NAME="Yesavage 1982" TYPE="JOURNAL_ARTICLE">
<AU>Yesavage JA, Tinklenberg JR, Hollister LE, Berger PA</AU>
<TI>Effect of nafronyl on lactate and pyruvate in the cerebrospinal fluid of patients with senile dementia</TI>
<SO>Journal of the American Geriatric Society</SO>
<YR>1982</YR>
<VL>30</VL>
<PG>105-8</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Admani-1978">
<CHAR_METHODS>
<P>RCT, single centre, 91 patients<BR/>R: numerical code<BR/>A: not stated<BR/>B: double blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Naftidrofuryl = 47, placebo = 44<BR/>Age (years): naftidrofuryl mean = 73.5 (SD 7.3), placebo mean = 73.2 (SD 6.5)<BR/>Sex (male:female): naftidrofuryl 25:22, placebo 20:24<BR/>Delay (days): naftidrofuryl mean = 5 (SD 5), placebo mean = 6 (SD 6)<BR/>In: ischaemic stroke<BR/>Ex: previous stroke, coma, dementia, confusion</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Active rx: 2 x 100 mg capsule thrice per day for 4 weeks, then 1 capsule thrice per day for 8 weeks<BR/>Control rx: placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) Hospital stay<BR/>(2) Neurophysical assessment<BR/>(3) Death<BR/>Assessed: 2, 4, 8, and 12 weeks post randomisation<BR/>Neurophysical score: 1 = poor, 2 = fair, 3 = good, 4 = normal</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>ITT analysis, no withdrawals</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Autret-1992">
<CHAR_METHODS>
<P>RCT, multicentre, 358 patients<BR/>R: blocks of 6 patients, previously drawn-up list<BR/>A: not stated<BR/>B: double blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Naftidrofuryl = 152, placebo = 160<BR/>Age (years): naftidrofuryl mean = 67.5 (SD 9.1), placebo mean = 68.0 (SD 8.5)<BR/>Sex (male:female): naftidrofuryl 94:58, placebo 94:66<BR/>Delay (days): overall mean 1.9<BR/>In: 40 to 80 years old, first ischaemic stroke, between 24 hours and 3 days post stroke, confirmed by CT scan<BR/>Ex: taking similar rx to active, or using a drug with anti-aggregant activity</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Active rx: 400 mg twice daily iv infusions for 7 days then 600 mg tablets per day for 6 months<BR/>Control rx: iv placebo, then oral placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) Daily Activities Evaluation Scale<BR/>(2) Limb Function Evaluation Scale<BR/>(3) Hospital stay<BR/>(4) Death<BR/>Assessed: 7, 21, 45, 90, and 180 days post randomisation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Not ITT analysis, since post randomisation patients were excluded</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Busse-1985">
<CHAR_METHODS>
<P>RCT, single centre, 62 patients<BR/>R: not stated<BR/>A: unclear<BR/>B: double blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Naftidrofuryl = 20, placebo = 21<BR/>Age (years): naftidrofuryl mean = 60.2, placebo mean = 59.1<BR/>Sex (male:female): not stated<BR/>Delay (days): not stated<BR/>In: less than 24 hours post ictus, CT-proven ischaemic stroke<BR/>Ex: previous stroke, TIA, unconsciousness, low neurological loss, subcortical or central infarct, steroids use</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Active rx: 800 mg iv naftidrofuryl infusion for 14 days, then 600 mg per day for 10 weeks<BR/>Control rx: placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) Combined neurological and functional score<BR/>(2) Death<BR/>Assessed: 7, 14, 21, 28 days and 3 months post randomisation<BR/>Combined neurological and functional score: 1 = low, 2 = moderate, 3 = severe, 4 = very severe</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Not ITT analysis, since post randomisation patients were excluded</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Gray-1990">
<CHAR_METHODS>
<P>RCT, 2 hospitals, 100 patients<BR/>R: performed by Lipha Pharmaceuticals and held by study hospitals<BR/>A: performed by Lipha Pharmaceuticals and held by study hospitals<BR/>B: double-blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Naftidrofuryl = 49, placebo = 51<BR/>Age (years): naftidrofuryl median = 70 (range 41 to 79), placebo median = 69 (range 40 to 80)<BR/>Sex (male:female): not stated<BR/>Delay (hours): naftidrofuryl median 22 (range 2 to 60), placebo median 22 (range 2 to 72)<BR/>In: less than 72 hours post stroke; hemisphere stroke; more than 24 hours symptoms; 40 to 80 years old; no history of previous major stroke; able to swallow; ambulant, continent and independent in self care prior to stroke; no malignant disease; no concomitant rx; no renal, metabolic, hepatic dysfunction; no gross haematological abnormality</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Active rx: 316.5 mg naftidrofuryl oxalate given as oral sustained release twice daily<BR/>Control rx: oral placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) Limb function (upper and lower)<BR/>(2) Limb power<BR/>(3) Discharge home<BR/>(4) Death<BR/>Assessment: 14, 28 days, and 26 weeks post randomisation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Sample size calculation performed based on previous studies with 90% power, 5% significance</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Steiner-1986">
<CHAR_METHODS>
<P>RCT, single hospital, 89 patients<BR/>R: stratification/matching based on time from onset, severity, age, sex, and side affected<BR/>A: dispensed by a pharmacist according to next number in a computer-randomised list of company-prepacked pre-coded matching active or placebo materials<BR/>B: double-blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Naftidrofuryl = 44, placebo = 45<BR/>Age (years): naftidrofuryl mean 69.2 (SD 8.6), placebo mean 69.9 (SD 6.6)<BR/>Sex (male:female): naftidrofuryl 24:20, placebo 25:20<BR/>Delay (hours): naftidrofuryl mean 73.2 (SD 49.9), placebo mean 66.1 (SD 50.4)<BR/>In: within 1 week of stroke, 40 to 80 years old, disabling hemiparesis, acute cerebral hemisphere infarction<BR/>Ex: not conscious, severe disability prior to stroke, intercurrent illness, incompatible with medication on admission</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Active rx: 600 mg iv naftidrofuryl for 10 days, then 3 x 100 mg capsule taken daily for 9 months<BR/>Control rx: iv and oral placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) Death<BR/>(2) Discharged from hospital<BR/>(3) Modified Rankin Score<BR/>Assessed: 1 week, 90 days, and 1 year post randomisation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>ITT analysis, 3 withdrawals</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Steiner-1996">
<CHAR_METHODS>
<P>RCT, multicentre, 620 patients<BR/>R: method similar to minimisation based on stratifying by age and stroke severity<BR/>A: dispensed by a pharmacist at each site, according to next number in a computer-randomised list, of company-prepacked pre-coded matching active or placebo materials<BR/>B: double-blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Naftidrofuryl = 313, placebo = 307<BR/>Age (years): naftidrofuryl = 72, placebo = 72<BR/>Sex (male:female): naftidrofuryl 161:152, placebo 160:147<BR/>Delay: not stated<BR/>In: 45 to 85 years old, up to 48 hours post stroke, confirmed by CT scan, conscious, disabled by stoke<BR/>Ex: comatose</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Active rx: 633 mg iv naftidrofuryl daily for 7 days, then oral sustained release 316.5 mg twice daily for 6 months<BR/>Control rx: iv placebo, then oral placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) Time to discharge<BR/>(2) Death<BR/>Assessed: at intervals to one year post randomisation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>ITT analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>A: allocation method<BR/>B: blinding method<BR/>CT: computerised tomography<BR/>Ex: exclusion criteria<BR/>In: inclusion criteria<BR/>ITT: intention to treat<BR/>iv: intravenous<BR/>R: randomisation method<BR/>RCT: randomised controlled trial<BR/>rx: treatment<BR/>SD: standard deviation<BR/>TIA: transient ischaemic attack</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Agnoli-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not acute stage of stroke</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Akopov-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Capon-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chodkiewicz-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>No control or comparison group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Delwaide-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ducarne-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not acute stage of stroke</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ishioka-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>No control or comparison group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Judge-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review, no new data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kobayaski-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Miyazaki-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nakano-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>No control or comparison group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Orgogozo-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not acute stage of stroke</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Otomo-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>No control or comparison group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Otomo-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Otomo-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Robinson-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Steiner-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review, no new data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-Litomericky-1982">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Admani-1978">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Autret-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Busse-1985">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Gray-1990">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Steiner-1986">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Steiner-1996">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Primary outcome measures</NAME>
<DICH_OUTCOME CHI2="1.8231027896610574" CI_END="1.3630936025775187" CI_START="0.7779285293700848" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0297521068912168" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="126" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.13452567952296202" LOG_CI_START="-0.1090603011156883" LOG_EFFECT_SIZE="0.012732689203636849" METHOD="MH" NO="1" P_CHI2="0.7682530010427365" P_Q="0.0" P_Z="0.8376487891876545" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="638" TOTAL_2="636" WEIGHT="100.0" Z="0.20490187653690023">
<NAME>Late death (at end of scheduled follow up)</NAME>
<GROUP_LABEL_1>Naftidrofuryl</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favour naftidrofuryl</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6215932221404439" CI_START="0.2416146601983378" EFFECT_SIZE="0.6259398496240601" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" LOG_CI_END="0.2099419204449695" LOG_CI_START="-0.6168767180224262" LOG_EFFECT_SIZE="-0.20346739878872833" ORDER="55318" O_E="0.0" SE="0.48567736105401677" STUDY_ID="STD-Admani-1978" TOTAL_1="47" TOTAL_2="51" VAR="0.23588249904039377" WEIGHT="8.679287256176194"/>
<DICH_DATA CI_END="1.5575788196081417" CI_START="0.5630836167655402" EFFECT_SIZE="0.9365079365079365" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="42" LOG_CI_END="0.19245003289445445" LOG_CI_START="-0.24942710851732944" LOG_EFFECT_SIZE="-0.028488537811437512" ORDER="55319" O_E="0.0" SE="0.2595608201924086" STUDY_ID="STD-Autret-1992" TOTAL_1="152" TOTAL_2="160" VAR="0.06737181937895587" WEIGHT="30.387957260892545"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="55320" O_E="0.0" SE="0.0" STUDY_ID="STD-Busse-1985" TOTAL_1="20" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.3087430014083496" CI_START="0.3945058866040578" EFFECT_SIZE="0.9543650793650794" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" LOG_CI_END="0.3633755919548093" LOG_CI_START="-0.40394651209819626" LOG_EFFECT_SIZE="-0.0202854600716935" ORDER="55321" O_E="0.0" SE="0.4507288022264088" STUDY_ID="STD-Gray-1990" TOTAL_1="49" TOTAL_2="51" VAR="0.20315645315645314" WEIGHT="10.077415391277972"/>
<DICH_DATA CI_END="2.732621470235603" CI_START="0.5318571245089271" EFFECT_SIZE="1.2055555555555555" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="15" LOG_CI_END="0.4365794762687727" LOG_CI_START="-0.27420501877832576" LOG_EFFECT_SIZE="0.08118722874522342" ORDER="55322" O_E="0.0" SE="0.41751833083066076" STUDY_ID="STD-Steiner-1986" TOTAL_1="57" TOTAL_2="46" VAR="0.1743215565796211" WEIGHT="11.74434193938135"/>
<DICH_DATA CI_END="1.885549161600035" CI_START="0.7690277403875283" EFFECT_SIZE="1.2041759053954175" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="41" LOG_CI_END="0.2754378601748286" LOG_CI_START="-0.11405799403480044" LOG_EFFECT_SIZE="0.08068993307001406" ORDER="55323" O_E="0.0" SE="0.22879179279830938" STUDY_ID="STD-Steiner-1996" TOTAL_1="313" TOTAL_2="307" VAR="0.052345684451864535" WEIGHT="39.110998152271925"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.377635139298344" CI_END="1.2569848534842165" CI_START="0.6961825936241862" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9354629738503601" ESTIMABLE="YES" EVENTS_1="231" EVENTS_2="230" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.09933004452139368" LOG_CI_START="-0.1572768394077611" LOG_EFFECT_SIZE="-0.0289733974431837" METHOD="MH" NO="2" P_CHI2="0.5021695504660534" P_Q="0.0" P_Z="0.658056709493211" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="381" TOTAL_2="369" WEIGHT="99.99999999999999" Z="0.4425977559829058">
<NAME>Late death or disability or dependency (at end of scheduled follow up)</NAME>
<GROUP_LABEL_1>Naftidrofuryl</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favour Naftidrofuryl</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5887665679040794" CI_START="0.1260746527253709" EFFECT_SIZE="0.44755244755244755" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.20106009247586545" LOG_CI_START="-0.899372219438215" LOG_EFFECT_SIZE="-0.3491560634811746" ORDER="55324" O_E="0.0" SE="0.6463993872461266" STUDY_ID="STD-Busse-1985" TOTAL_1="19" TOTAL_2="21" VAR="0.4178321678321678" WEIGHT="5.437633564810226"/>
<DICH_DATA CI_END="2.1197285103613077" CI_START="0.43477265861886877" EFFECT_SIZE="0.96" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="25" LOG_CI_END="0.3262802411163738" LOG_CI_START="-0.361737775037237" LOG_EFFECT_SIZE="-0.017728766960431602" ORDER="55325" O_E="0.0" SE="0.40414518843273806" STUDY_ID="STD-Steiner-1986" TOTAL_1="55" TOTAL_2="45" VAR="0.16333333333333333" WEIGHT="13.910315634254786"/>
<DICH_DATA CI_END="1.3600058350718947" CI_START="0.7043810178853467" EFFECT_SIZE="0.9787554824561403" ESTIMABLE="YES" EVENTS_1="193" EVENTS_2="192" LOG_CI_END="0.1335407717041065" LOG_CI_START="-0.15219235619528848" LOG_EFFECT_SIZE="-0.00932579224559103" ORDER="55326" O_E="0.0" SE="0.1678410537298989" STUDY_ID="STD-Steiner-1996" TOTAL_1="307" TOTAL_2="303" VAR="0.02817061931716281" WEIGHT="80.65205080093497"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Secondary outcome measures</NAME>
<DICH_OUTCOME CHI2="0.3561388756445474" CI_END="1.9138708720502782" CI_START="0.6329288458057285" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.1006107768271152" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.2819126327888856" LOG_CI_START="-0.1986451108529036" LOG_EFFECT_SIZE="0.04163376096799105" METHOD="MH" NO="1" P_CHI2="0.5506586901946744" P_Q="0.0" P_Z="0.7341516124679301" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="221" TOTAL_2="232" WEIGHT="100.0" Z="0.3396081870196125">
<NAME>Early death (within one month of randomisation)</NAME>
<GROUP_LABEL_1>Naftidrofuryl</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favour Naftidrofuryl</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8792101604558609" CI_START="0.5431955867907801" EFFECT_SIZE="1.0103359173126616" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="24" LOG_CI_END="0.27397535190598243" LOG_CI_START="-0.26504376715207156" LOG_EFFECT_SIZE="0.004465792376955446" ORDER="55327" O_E="0.0" SE="0.31662249872237225" STUDY_ID="STD-Autret-1992" TOTAL_1="152" TOTAL_2="160" VAR="0.1002498066971986" WEIGHT="79.48456828942724"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="55328" O_E="0.0" SE="0.0" STUDY_ID="STD-Busse-1985" TOTAL_1="20" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.2014472426833525" CI_START="0.45201095030201754" EFFECT_SIZE="1.5333333333333334" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.7161241978776264" LOG_CI_START="-0.3448510439538031" LOG_EFFECT_SIZE="0.18563657696191166" ORDER="55329" O_E="0.0" SE="0.6232221089639305" STUDY_ID="STD-Gray-1990" TOTAL_1="49" TOTAL_2="51" VAR="0.3884057971014493" WEIGHT="20.515431710572763"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.02" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="161" TOTAL_2="162" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Length of stay</NAME>
<GROUP_LABEL_1>Naftidrofuryl</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favour naftidrofuryl</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-16.839848940232507" CI_START="-33.56015105976749" EFFECT_SIZE="-25.2" ESTIMABLE="YES" MEAN_1="26.13" MEAN_2="51.33" ORDER="55330" SD_1="19.54" SD_2="21.05" SE="4.26546157261628" STUDY_ID="STD-Admani-1978" TOTAL_1="47" TOTAL_2="44" WEIGHT="0.0"/>
<CONT_DATA CI_END="-0.0015542183864072356" CI_START="-14.998445781613594" EFFECT_SIZE="-7.5" ESTIMABLE="YES" MEAN_1="25.5" MEAN_2="33.0" ORDER="55331" SD_1="17.4" SD_2="37.6" SE="3.8258079437991594" STUDY_ID="STD-Autret-1992" TOTAL_1="114" TOTAL_2="118" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.066640169203729" CI_END="1.691808020307834" CI_START="0.6447476083909391" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0444085287616554" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="79" I2="3.2245656596041643" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.22835107947644445" LOG_CI_START="-0.1906102601470538" LOG_EFFECT_SIZE="0.018870409664695338" METHOD="MH" NO="3" P_CHI2="0.35582378278520443" P_Q="0.0" P_Z="0.859856204858603" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.005871181768473329" TOTALS="YES" TOTAL_1="142" TOTAL_2="141" WEIGHT="100.00000000000001" Z="0.17655721336749802">
<NAME>Discharged</NAME>
<GROUP_LABEL_1>Naftidrofuryl</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favour Naftidrofuryl</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8207773250189783" CI_START="0.35027880566530883" EFFECT_SIZE="0.7986111111111112" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="24" LOG_CI_END="0.26025683627887586" LOG_CI_START="-0.45558613976215173" LOG_EFFECT_SIZE="-0.09766465174163795" ORDER="55332" O_E="0.0" SE="0.42048970760637955" STUDY_ID="STD-Admani-1978" TOTAL_1="47" TOTAL_2="44" VAR="0.17681159420289855" WEIGHT="33.15320360449037"/>
<DICH_DATA CI_END="1.8868710884558775" CI_START="0.3897608014954463" EFFECT_SIZE="0.8575712143928036" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="29" LOG_CI_END="0.2757422300617532" LOG_CI_START="-0.4092018403088027" LOG_EFFECT_SIZE="-0.06672980512352478" ORDER="55333" O_E="0.0" SE="0.4023395374634946" STUDY_ID="STD-Gray-1990" TOTAL_1="49" TOTAL_2="51" VAR="0.1618771034063388" WEIGHT="36.10480584347456"/>
<DICH_DATA CI_END="4.142097084306929" CI_START="0.7463403241168444" EFFECT_SIZE="1.7582417582417582" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="26" LOG_CI_END="0.6172202738632414" LOG_CI_START="-0.12706309319357906" LOG_EFFECT_SIZE="0.24507859033483118" ORDER="55334" O_E="0.0" SE="0.4371957340712623" STUDY_ID="STD-Steiner-1986" TOTAL_1="46" TOTAL_2="46" VAR="0.19114010989010988" WEIGHT="30.74199055203508"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="2.7765974701533476" CI_END="3.488628348939006" CI_START="-1.3610472708484307" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.0637905390452878" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.04" NO="4" P_CHI2="0.42736698265543505" P_Q="0.737010905111461" P_Z="0.38987302608945684" Q="0.11277128382381774" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="689" TOTAL_2="668" UNITS="" WEIGHT="200.0" Z="0.8598476710962373">
<NAME>Systolic blood pressure (mm Hg)</NAME>
<GROUP_LABEL_1>Naftidrofuryl</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favour naftidrofuryl</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.027034902124308494" CI_END="5.019696328109262" CI_START="-2.0182423223362993" DF="1.0" EFFECT_SIZE="1.5007270028864812" ESTIMABLE="YES" I2="0.0" ID="CMP-002.04.01" NO="1" P_CHI2="0.8693982328199314" P_Z="0.40323284806623827" STUDIES="2" TAU2="0.0" TOTAL_1="355" TOTAL_2="346" WEIGHT="100.0" Z="0.8358614709146485">
<NAME>24 hour on treatment</NAME>
<CONT_DATA CI_END="10.297744884394243" CI_START="-6.057744884394291" EFFECT_SIZE="2.119999999999976" ESTIMABLE="YES" MEAN_1="142.89" MEAN_2="140.77" ORDER="55335" SD_1="19.38" SD_2="18.8" SE="4.172395487314703" STUDY_ID="STD-Steiner-1986" TOTAL_1="45" TOTAL_2="39" WEIGHT="18.51671090611811"/>
<CONT_DATA CI_END="5.2583533876228685" CI_START="-2.5383533876228976" EFFECT_SIZE="1.3599999999999852" ESTIMABLE="YES" MEAN_1="155.7" MEAN_2="154.34" ORDER="55336" SD_1="24.45" SD_2="24.95" SE="1.9889923582130062" STUDY_ID="STD-Steiner-1996" TOTAL_1="310" TOTAL_2="307" WEIGHT="81.4832890938819"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.6367912842052212" CI_END="6.899998793608766" CI_START="-9.986908150049175" DF="1.0" EFFECT_SIZE="-1.5434546782202037" ESTIMABLE="YES" I2="62.075117359870255" ID="CMP-002.04.02" NO="2" P_CHI2="0.10441428985498658" P_Z="0.7201342212240569" STUDIES="2" TAU2="25.308304685647396" TOTAL_1="334" TOTAL_2="322" WEIGHT="100.0" Z="0.3582794162571698">
<NAME>48 hour on treatment</NAME>
<CONT_DATA CI_END="2.899224168524162" CI_START="-17.719224168524214" EFFECT_SIZE="-7.410000000000025" ESTIMABLE="YES" MEAN_1="139.89" MEAN_2="147.3" ORDER="55337" SD_1="20.01" SD_2="26.21" SE="5.2599049012339165" STUDY_ID="STD-Steiner-1986" TOTAL_1="44" TOTAL_2="37" WEIGHT="10.534408364592215"/>
<CONT_DATA CI_END="5.157553681920213" CI_START="-1.9175536819202041" EFFECT_SIZE="1.6200000000000045" ESTIMABLE="YES" MEAN_1="152.29" MEAN_2="150.67" ORDER="55338" SD_1="22.74" SD_2="20.5" SE="1.8049074931090472" STUDY_ID="STD-Steiner-1996" TOTAL_1="290" TOTAL_2="285" WEIGHT="89.46559163540779"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.482348819926624" CI_END="2.3552722537986335" CI_START="-1.2229908315351392" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5661407111317472" ESTIMABLE="YES" I2="33.07080460442368" I2_Q="0.0" ID="CMP-002.05" NO="5" P_CHI2="0.21387043929807092" P_Q="0.38884045751488394" P_Z="0.5351275889311545" Q="0.7425650845438203" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="1.07201587279292" TOTALS="SUB" TOTAL_1="689" TOTAL_2="668" UNITS="" WEIGHT="200.0" Z="0.6201977761490484">
<NAME>Diastolic blood pressure (mm Hg)</NAME>
<GROUP_LABEL_1>Naftidrofuryl</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favour naftidrofuryl</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.2864290794627773" CI_END="3.8159974653708235" CI_START="-1.4971460605926485" DF="1.0" EFFECT_SIZE="1.1594257023890875" ESTIMABLE="YES" I2="22.26543880540949" ID="CMP-002.05.01" NO="1" P_CHI2="0.2567071811703693" P_Z="0.39232951622255574" STUDIES="2" TAU2="1.2718463954425976" TOTAL_1="355" TOTAL_2="346" WEIGHT="100.0" Z="0.8554004266318365">
<NAME>24 hour on treatment</NAME>
<CONT_DATA CI_END="3.9521717824561264" CI_START="-7.0321717824561105" EFFECT_SIZE="-1.539999999999992" ESTIMABLE="YES" MEAN_1="83.56" MEAN_2="85.1" ORDER="55339" SD_1="11.06" SD_2="14.15" SE="2.8021799511509746" STUDY_ID="STD-Steiner-1986" TOTAL_1="45" TOTAL_2="39" WEIGHT="19.052701491672245"/>
<CONT_DATA CI_END="3.8276921679295945" CI_START="-0.14769216792958795" EFFECT_SIZE="1.8400000000000034" ESTIMABLE="YES" MEAN_1="87.8" MEAN_2="85.96" ORDER="55340" SD_1="12.55" SD_2="12.64" SE="1.0141472923014165" STUDY_ID="STD-Steiner-1996" TOTAL_1="310" TOTAL_2="307" WEIGHT="80.94729850832775"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.4533546559200268" CI_END="3.666998966705404" CI_START="-5.41890767523314" DF="1.0" EFFECT_SIZE="-0.8759543542638683" ESTIMABLE="YES" I2="59.23948469549779" ID="CMP-002.05.02" NO="2" P_CHI2="0.11727423192930775" P_Z="0.7054955742329921" STUDIES="2" TAU2="7.169873311665498" TOTAL_1="334" TOTAL_2="322" WEIGHT="99.99999999999999" Z="0.3779125307173355">
<NAME>48 hour on treatment</NAME>
<CONT_DATA CI_END="1.715850185415654" CI_START="-10.035850185415647" EFFECT_SIZE="-4.159999999999997" ESTIMABLE="YES" MEAN_1="82.73" MEAN_2="86.89" ORDER="55341" SD_1="10.37" SD_2="15.56" SE="2.9979378354722876" STUDY_ID="STD-Steiner-1986" TOTAL_1="44" TOTAL_2="37" WEIGHT="16.244185608450945"/>
<CONT_DATA CI_END="2.5975873429819907" CI_START="-1.0775873429819804" EFFECT_SIZE="0.7600000000000051" ESTIMABLE="YES" MEAN_1="84.68" MEAN_2="83.92" ORDER="55342" SD_1="11.19" SD_2="11.29" SE="0.9375617906638285" STUDY_ID="STD-Steiner-1996" TOTAL_1="290" TOTAL_2="285" WEIGHT="83.75581439154904"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.6009988851564296" CI_END="2.642068754679586" CI_START="-0.8790239356556385" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.8815224095119737" ESTIMABLE="YES" I2="16.68978259431818" I2_Q="0.0" ID="CMP-002.06" NO="6" P_CHI2="0.30789738559615" P_Q="0.6293699361992627" P_Z="0.32640898126662055" Q="0.2329161690256032" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.5867055620785738" TOTALS="SUB" TOTAL_1="689" TOTAL_2="668" UNITS="" WEIGHT="200.0" Z="0.9813727306587589">
<NAME>Mean arterial blood pressure (mm Hg)</NAME>
<GROUP_LABEL_1>Naftidrofuryl</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favour naftidrofuryl</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.3698301980798722" CI_END="3.6151774877573994" CI_START="-0.7920429898353256" DF="1.0" EFFECT_SIZE="1.411567248961037" ESTIMABLE="YES" I2="0.0" ID="CMP-002.06.01" NO="1" P_CHI2="0.5430971155271533" P_Z="0.20929925641254365" STUDIES="2" TAU2="0.0" TOTAL_1="355" TOTAL_2="346" WEIGHT="99.99999999999999" Z="1.255494697297775">
<NAME>24 hour on treatment</NAME>
<CONT_DATA CI_END="5.699968718485807" CI_START="-6.359968718485804" EFFECT_SIZE="-0.3299999999999983" ESTIMABLE="YES" MEAN_1="103.33" MEAN_2="103.66" ORDER="55343" SD_1="12.99" SD_2="14.93" SE="3.076571185006168" STUDY_ID="STD-Steiner-1986" TOTAL_1="45" TOTAL_2="39" WEIGHT="16.909267617959927"/>
<CONT_DATA CI_END="4.047351172144614" CI_START="-0.6873511721446004" EFFECT_SIZE="1.6800000000000068" ESTIMABLE="YES" MEAN_1="110.43" MEAN_2="108.75" ORDER="55344" SD_1="14.88" SD_2="15.12" SE="1.2078544252945316" STUDY_ID="STD-Steiner-1996" TOTAL_1="310" TOTAL_2="307" WEIGHT="83.09073238204006"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.998252518050954" CI_END="4.959725891261" CI_START="-7.20083391157087" DF="1.0" EFFECT_SIZE="-1.1205540101549347" ESTIMABLE="YES" I2="66.64723888399965" ID="CMP-002.06.02" NO="2" P_CHI2="0.08335457299160576" P_Z="0.7179439923835595" STUDIES="2" TAU2="13.906479571057565" TOTAL_1="334" TOTAL_2="322" WEIGHT="100.0" Z="0.3612079605289479">
<NAME>48 hour on treatment</NAME>
<CONT_DATA CI_END="1.7538872215951864" CI_START="-12.253887221595186" EFFECT_SIZE="-5.25" ESTIMABLE="YES" MEAN_1="101.78" MEAN_2="107.03" ORDER="55345" SD_1="12.96" SD_2="18.2" SE="3.5734775112404895" STUDY_ID="STD-Steiner-1986" TOTAL_1="44" TOTAL_2="37" WEIGHT="11.500125355299794"/>
<CONT_DATA CI_END="3.310821144879014" CI_START="-0.8908211448790264" EFFECT_SIZE="1.2099999999999937" ESTIMABLE="YES" MEAN_1="107.38" MEAN_2="106.17" ORDER="55346" SD_1="13.14" SD_2="12.56" SE="1.071867218709134" STUDY_ID="STD-Steiner-1996" TOTAL_1="290" TOTAL_2="285" WEIGHT="88.4998746447002"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.6538429867075485" CI_END="4.35003622772443" CI_START="0.533987260598971" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.5240944618851058" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="0.6384928738363146" LOG_CI_START="-0.2724691038657614" LOG_EFFECT_SIZE="0.18301188498527662" METHOD="MH" NO="7" P_CHI2="0.7211404146439986" P_Q="0.0" P_Z="0.4309822663316606" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="216" TOTAL_2="226" WEIGHT="99.99999999999999" Z="0.7875119095941856">
<NAME>Serious adverse events (requiring withdrawal of the treatment)</NAME>
<GROUP_LABEL_1>Naftidrofuryl</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favour naftidrofuryl</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="11.830161055000556" CI_START="0.38535418276165795" EFFECT_SIZE="2.135135135135135" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0729906571234424" LOG_CI_START="-0.4141399226765494" LOG_EFFECT_SIZE="0.3294253672234464" ORDER="55347" O_E="0.0" SE="0.8735478639896085" STUDY_ID="STD-Autret-1992" TOTAL_1="152" TOTAL_2="160" VAR="0.7630858706808075" WEIGHT="37.523409490154854"/>
<DICH_DATA CI_END="86.05765555743793" CI_START="0.12713370276586916" EFFECT_SIZE="3.3076923076923075" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.934789510555081" LOG_CI_START="-0.8957393040095816" LOG_EFFECT_SIZE="0.5195251032727497" ORDER="55348" O_E="0.0" SE="1.662666637018887" STUDY_ID="STD-Busse-1985" TOTAL_1="20" TOTAL_2="21" VAR="2.764460345855695" WEIGHT="10.357747993973927"/>
<DICH_DATA CI_END="4.381691541787215" CI_START="0.2397761207014286" EFFECT_SIZE="1.025" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.64164180124503" LOG_CI_START="-0.6201940704614838" LOG_EFFECT_SIZE="0.010723865391773066" ORDER="55349" O_E="0.0" SE="0.7412086372287084" STUDY_ID="STD-Steiner-1986" TOTAL_1="44" TOTAL_2="45" VAR="0.5493902439024391" WEIGHT="52.11884251587121"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.946318882084349" CI_END="4.1073294699957" CI_START="0.9601434434612662" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.9858563545109726" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="0.6135595412422719" LOG_CI_START="-0.017663879408388476" LOG_EFFECT_SIZE="0.2979478309169417" METHOD="MH" NO="8" P_CHI2="0.6230307675508829" P_Q="0.0" P_Z="0.0642745810137362" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="243" TOTAL_2="249" WEIGHT="100.0" Z="1.8502704391642713">
<NAME>Minor adverse events (not requiring withdrawal of the treatment)</NAME>
<GROUP_LABEL_1>Naftidrofuryl</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favour naftidrofuryl</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="45.68184490621037" CI_START="0.5736337615058672" EFFECT_SIZE="5.119047619047619" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.659743635001524" LOG_CI_START="-0.24136529596611425" LOG_EFFECT_SIZE="0.7091891695177048" ORDER="55350" O_E="0.0" SE="1.116720796691372" STUDY_ID="STD-Admani-1978" TOTAL_1="47" TOTAL_2="44" VAR="1.2470653377630123" WEIGHT="11.024329994830138"/>
<DICH_DATA CI_END="3.771055477411752" CI_START="0.7715330787323592" EFFECT_SIZE="1.7057239057239058" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="11" LOG_CI_END="0.5764629215216555" LOG_CI_START="-0.11264544924702176" LOG_EFFECT_SIZE="0.23190873613731683" ORDER="55351" O_E="0.0" SE="0.4047856681309705" STUDY_ID="STD-Autret-1992" TOTAL_1="152" TOTAL_2="160" VAR="0.16385143712423617" WEIGHT="83.90564068223362"/>
<DICH_DATA CI_END="79.12617200609999" CI_START="0.12444189991158604" EFFECT_SIZE="3.1379310344827585" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8983201557838618" LOG_CI_START="-0.9050333669395867" LOG_EFFECT_SIZE="0.49664339442213745" ORDER="55352" O_E="0.0" SE="1.6467037360714936" STUDY_ID="STD-Steiner-1986" TOTAL_1="44" TOTAL_2="45" VAR="2.711633194391815" WEIGHT="5.070029322936235"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-09-03 19:39:48 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2008-09-03 19:39:48 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-09-03 19:39:46 +0100" MODIFIED_BY="[Empty name]">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-09-03 19:39:48 +0100" MODIFIED_BY="[Empty name]">
<P>We used the following search strategy, employing a combination of controlled vocabulary (/) and free text terms (tw), for MEDLINE (Ovid) and we adapted it to suit the other databases. Due to the specific nature of the intervention under investigation for this review, we anticipated that relatively few references would be retrieved; therefore, we did not use the Cochrane search strategy for locating randomised controlled trials.</P>
<P>
<B>MEDLINE (Ovid)</B>
<BR/>1. Cerebrovascular disorders/<BR/>2. exp Brain ischemia/<BR/>3. Carotid artery diseases/ or Carotid artery thrombosis/<BR/>4. exp Cerebrovascular accident/<BR/>5. exp Hypoxia-ischemia, brain/<BR/>6. Cerebral arterial diseases/ or Intracranial arterial diseases/<BR/>7. exp "Intracranial embolism and thrombosis"/<BR/>8. exp basal ganglia cerebrovascular disease/<BR/>9. exp intracranial hemorrhages/<BR/>10. (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva or transient isch?emic attack$ or tia$).tw.<BR/>11. (brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or infratentorial or supratentorial or middle cerebr$ or mca$ or anterior circulation).tw.<BR/>12. (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$).tw.<BR/>13. 11 and 12<BR/>14. (brain or cerebral or intracranial or subarachnoid).tw.<BR/>15. (haemorrhage or hemorrhage or haematoma or hematoma or aneurysm or bleed$).tw.<BR/>16. 14 and 15<BR/>17. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 13 or 16<BR/>18. nafronyl/ or furans/<BR/>19. (naftidrofur$ or nafronyl$ or naftifurin or naftirofuryl or naphthydrofur$ or naphthohydrofur$).tw.<BR/>20. (praxilene or dusodril or LS 121 or LS121 or artocoron or EU 1806 or EU1806 or gevatran or iridus or sodipryl or di-actane or vascuprax).tw.<BR/>21. 18 or 19 or 20<BR/>22. 17 and 21<BR/>23. limit 22 to human</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>